[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 234
1. Stranahan D, Cherpelis BS, Glass LF, Ladd S, Fenske NA: Immunohistochemical stains in Mohs surgery: a review. Dermatol Surg; 2009 Jul;35(7):1023-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: During Mohs surgery, there are instances in which residual tumor cells may be difficult to detect, thereby increasing the risk of incomplete excision and tumor recurrence.
  • RESULTS: Various immunostains have proved useful in detecting tumor cells in various malignancies, including melanoma, basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, extramammary Paget's disease, primary cutaneous mucinous carcinoma, granular cell tumor, and trichilemmal carcinoma.
  • CONCLUSIONS: In this article, we review immunohistochemical stains that have been employed in Mohs micrographic surgery and evaluate their utility in enhancing detection of residual tumors with respect to tumor type, particularly in situations in which detection of residual tumor may be difficult.
  • [MeSH-major] Coloring Agents. Immunohistochemistry / methods. Mohs Surgery. Neoplasm, Residual / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19397647.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Coloring Agents
  • [Number-of-references] 45
  •  go-up   go-down


2. Rodríguez-Domínguez FJ, Hernández-Gil J, Segarra Fenoll JD, Hernández-Gil A: [Facial mutilant basosquamous carcinoma]. An Otorrinolaringol Ibero Am; 2007;34(6):549-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Facial mutilant basosquamous carcinoma].
  • [Transliterated title] Carcinoma basoescamoso mutilante en región facial.
  • Basosquamous carcinoma is a rare epithelial malignant neoplasm with clinical and biological features of both basal and squamous cell carcinoma.
  • This neoplasm has been characterized for years as a variant of basal cell carcinoma, although now it is widely accepted as a clinical entity.
  • The most important features of basosquamous carcinoma are its great local aggressiveness, high frequency of recurrences and its metastatic potential.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Head and Neck Neoplasms / pathology. Palliative Care / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Face. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18293774.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


3. Jensen AO, Svaerke C, Farkas D, Pedersen L, Kragballe K, Sørensen HT: Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark. Acta Derm Venereol; 2010 Sep;90(5):474-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer risk among solid organ recipients: a nationwide cohort study in Denmark.
  • This study assessed the risk of skin cancer following transplantation of 4 types of solid organs, and the risk of skin cancer in patients with chronic diseases that lead to organ transplantations.
  • Linkage to the Danish Cancer Registry allowed complete follow-up for basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • The SIR for squamous cell carcinoma was highest among heart (SIR = 113; 95% CI: 74-166), then renal (SIR = 81; 95% CI: 68-96), lung (SIR = 65; 95% CI: 28-128) and liver (SIR = 60; 95% CI: 27-113) recipients.
  • SIR for squamous cell carcinoma was 4.8 (95% CI: 2.2-9.0) among renal failure patients, but not greatly elevated among patients with the other chronic diseases studied.
  • Organ transplantation is a risk factor for squamous cell carcinoma, with immunosuppressive treatments being the most likely explanation for the association.
  • [MeSH-major] Organ Transplantation / adverse effects. Skin Neoplasms / epidemiology. Skin Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Child. Child, Preschool. Chronic Disease. Cohort Studies. Denmark / epidemiology. Female. Heart Diseases / epidemiology. Heart Transplantation / adverse effects. Humans. Immunosuppressive Agents / adverse effects. Incidence. Infant. Infant, Newborn. Kidney Diseases / epidemiology. Kidney Transplantation / adverse effects. Liver Diseases / epidemiology. Liver Transplantation / adverse effects. Lung Diseases / epidemiology. Lung Transplantation / adverse effects. Male. Melanoma / epidemiology. Melanoma / etiology. Middle Aged. Registries. Risk Assessment. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2010 Sep;90(5):450-3 [20814615.001]
  • (PMID = 20814621.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


Advertisement
4. Ducic Y, Marra DE, Kennard C: Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck. Laryngoscope; 2009 Apr;119(4):774-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial Mohs surgery followed by planned surgical resection of massive cutaneous carcinomas of the head and neck.
  • OBJECTIVE: To review our experience with Mohs excision of massive cutaneous carcinomas for peripheral margin control, followed by planned definitive resection of the deeply invasive component of the carcinoma.
  • METHODS: All cases of massive (at least 10 cm in dimension) cutaneous carcinomas treated by the technique outlined by Yadranko Ducic from 1998-2006.
  • RESULTS: A total of 28 cases (7 squamous cell carcinomas, 14 basal cell carcinomas, 7 basosquamous carcinomas) were treated in this manner.
  • Average maximal tumor dimension was 12.7 cm with a range of 10-21 cm.
  • There were a total of 7 local recurrences (5 squamous cell carcinoma and 2 basal cell carcinoma).
  • CONCLUSIONS: The technique appears to be an excellent means of treatment of massive, neglected, and deeply invasive cutaneous carcinomas of the face and neck.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Basosquamous / surgery. Carcinoma, Squamous Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery / methods. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205010.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, Roenigk RK: Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA; 2005 Aug 10;294(6):681-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years.
  • CONTEXT: The incidence of nonmelanoma skin cancer is increasing rapidly among elderly persons, but little is known about its incidence in the population younger than 40 years.
  • OBJECTIVES: To estimate the sex- and age-specific incidences of basal cell carcinoma and squamous cell carcinoma in persons younger than 40 years in Olmsted County, Minnesota, and to evaluate change in incidence over time; to describe the clinical presentation, rate of recurrence and metastasis, and histologic characteristics of these tumors in this population-based sample.
  • PARTICIPANTS: Patients younger than 40 years with basal cell carcinoma or squamous cell carcinoma diagnosed between 1976 and 2003.
  • MAIN OUTCOME MEASURES: Incident basal cell carcinomas and squamous cell carcinomas and change in incidence of these tumors over time.
  • RESULTS: During the study period, 451 incident basal cell carcinomas were diagnosed in 417 patients and 70 incident squamous cell carcinomas were diagnosed in 68 patients.
  • Of these tumors, 328 were histologically confirmed basal cell carcinomas and 51 were histologically confirmed squamous cell carcinomas.
  • Overall, the age-adjusted incidence of basal cell carcinoma per 100,000 persons was 25.9 (95% confidence interval [CI], 22.6-29.2) for women and 20.9 (95% CI, 17.8-23.9) for men.
  • The incidence of basal cell carcinoma increased significantly during the study period among women (P<.001) but not men (P = .19).
  • Nodular basal cell carcinoma was the most common histologic subtype; 43.0% of tumors were solely nodular basal cell carcinoma and 11.0% had a mixed composition, including the nodular subtype.
  • The incidence of squamous cell carcinoma was similar in men and women, with an average age- and sex-adjusted incidence per 100 000 persons of 3.9 (95% CI, 3.0-4.8); the incidence of squamous cell carcinoma increased significantly over the study period among both women (P = .01) and men (P = .04).
  • CONCLUSIONS: This population-based study demonstrated an increase in the incidence of nonmelanoma skin cancer among young women and men residing in Olmsted County, Minnesota.
  • There was a disproportionate increase in basal cell carcinoma in young women.
  • This increase may lead to an exponential increase in the overall occurrence of nonmelanoma skin cancers over time as this population ages, which emphasizes the need to focus on skin cancer prevention in young adults.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418458.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):279; author reply 279-81 [16418459.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278-9; author reply 279-81 [16418456.001]
  • [CommentIn] JAMA. 2006 Jan 18;295(3):278; author reply 279-81 [16418457.001]
  • (PMID = 16091570.001).
  • [ISSN] 1538-3598
  • [Journal-full-title] JAMA
  • [ISO-abbreviation] JAMA
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Takenouchi T: [Diagnosis and treatment for squamous cell carcinoma and basal cell carcinoma of skin]. Gan To Kagaku Ryoho; 2008 Apr;35(4):591-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment for squamous cell carcinoma and basal cell carcinoma of skin].
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / therapy. Skin Neoplasms / diagnosis. Skin Neoplasms / therapy
  • [MeSH-minor] Biopsy. Dermoscopy. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18468002.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Zalaudek I, Kreusch J, Giacomel J, Ferrara G, Catricalà C, Argenziano G: How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors. J Am Acad Dermatol; 2010 Sep;63(3):377-86; quiz 387-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to diagnose nonpigmented skin tumors: a review of vascular structures seen with dermoscopy: part II. Nonmelanocytic skin tumors.
  • Nonmelanoma skin cancer refers to a broad class of tumors, including actinic keratosis, basal cell carcinoma, and squamous cell carcinoma, and as a group these are the most frequent cancers occurring in light skinned humans.
  • In contrast to the rarity of amelanotic melanoma, nonmelanoma skin cancer commonly lacks pigmentation.
  • Dermoscopy improves the clinical diagnosis of nonpigmented skin tumors by allowing the visualization of specific vascular structures that are usually not visible to the naked eye.
  • Dermoscopic vascular patterns of several nonmelanocytic nonpigmented skin tumors, such as sebaceous hyperplasia, seborrheic keratosis, clear cell acanthoma, Bowen disease, or nodular cystic basal cell carcinoma are highly specific, allowing a ready diagnosis in most cases.
  • In the second part of this review of dermoscopic vascular structures of nonpigmented skin tumors, the dermoscopic patterns associated with benign and malignant nonmelanocytic skin tumors and recommendations for the management of these tumors will be discussed.
  • [MeSH-major] Dermoscopy / methods. Skin / blood supply. Skin Neoplasms / blood supply. Skin Neoplasms / diagnosis
  • [MeSH-minor] Blood Vessels / pathology. Bowen's Disease / blood supply. Bowen's Disease / diagnosis. Bowen's Disease / pathology. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / pathology. Diagnosis, Differential. Education, Medical, Continuing. Female. Humans. Keratosis, Seborrheic / diagnosis. Keratosis, Seborrheic / pathology. Male. Melanoma, Amelanotic / blood supply. Melanoma, Amelanotic / diagnosis. Melanoma, Amelanotic / pathology


8. Pătraşcu V, Stoica LE, Georgescu CV, Pătru E: Histopathological and clinical-progressive profile of skin carcinomas: study on 1688 cases. Rom J Morphol Embryol; 2010;51(1):171-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histopathological and clinical-progressive profile of skin carcinomas: study on 1688 cases.
  • Skin carcinomas represent 90-95% of skin cancers.
  • With the objective of identifying the histopathological and clinical-progressive profile of skin carcinomas, we undertook a retrospective study over a period of seven years, which included a total of 1688 patients with carcinoma of the skin, hospitalized and treated in Craiova Dermatology Clinic between January 1999 and December 2006.
  • Patient data such as identification data, environment, profession, phototype, location of cancer, history of the disease, clinical diagnosis, histopathological diagnosis and response to treatment were included in clinical charts.
  • Basal cell carcinoma (BCC) was diagnosed in a total of 1162 patients, representing 68.84% of cases taken to the study.
  • The most common clinical forms were: pearly BCC (37.95%), nodular BCC (29%), and superficial BCC (22.03%).
  • Regarding the histological type, the most frequent forms were: BCC polymorphic (29.95%), BCC solid (24.96%), and keratinized BCC (19.97%).
  • Epidermoid carcinoma (EC) was encountered in a total of 482 patients, representing 28.55% of all cases.
  • Metatypical carcinoma (MC) was found in 44 patients (2.61%).
  • This type of cancer did not presented clinical particular signs, the diagnosis was strictly pathological.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Disease Progression. Female. Humans. Male. Middle Aged. Prevalence. Retrospective Studies. Rural Population / statistics & numerical data. Urban Population / statistics & numerical data. Young Adult

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20191140.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  •  go-up   go-down


9. Diepgen TL: [Epidemiology of chronic UV-damage]. J Dtsch Dermatol Ges; 2005 Sep;3 Suppl 2:S32-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whereas in Australia the high incidence of UV-induced skin cancer and chronic UV-damage is epidemiologically well proved, comparable figures in Europe and particularly in Germany are missing.
  • Presumably, the prevalence and incidence of actinic keratoses, basal cell carcinoma and squamous cell carcinoma are significantly underestimated.
  • The importance of chronic skin damage is discussed in accordance with new epidemiologic studies recently published in international journals.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasms, Radiation-Induced / epidemiology. Photosensitivity Disorders / epidemiology. Skin Neoplasms / epidemiology. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16117742.001).
  • [ISSN] 1610-0379
  • [Journal-full-title] Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG
  • [ISO-abbreviation] J Dtsch Dermatol Ges
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


10. Terziqi H, Tarpila E: Reconstruction of large defect of lower lip and commissure using Karapandzic flap: case report. Niger J Med; 2009 Apr-Jun;18(2):222-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma Pigmentosum (XP) is a photosensitive skin disease with a high risk for developing skin malignancy.
  • We present an 18-years-old boy with XP and recurrent basal and squamous cell carcinoma of lower lip.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Lip Neoplasms / surgery. Reconstructive Surgical Procedures. Surgical Flaps. Xeroderma Pigmentosum / pathology
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Recurrence, Local / surgery

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19630336.001).
  • [ISSN] 1115-2613
  • [Journal-full-title] Nigerian journal of medicine : journal of the National Association of Resident Doctors of Nigeria
  • [ISO-abbreviation] Niger J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


11. Verhoeven RH, Louwman WJ, Koldewijn EL, Demeyere TB, Coebergh JW: Scrotal cancer: incidence, survival and second primary tumours in the Netherlands since 1989. Br J Cancer; 2010 Oct 26;103(9):1462-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The overall incidence rate varied around 1.5 per 1,000,000 person-years, most frequently being squamous cell carcinoma (27%), basal cell carcinoma (19%) and Bowen's disease (15%).
  • Overall 5-year relative survival was 82%, being 77% and 95% for patients with squamous and basal cell carcinoma, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Stat Med. 2000 Feb 15;19(3):335-51 [10649300.001]
  • [Cites] Urology. 2008 Nov;72(5):1139-43 [18799208.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):33-9 [12077578.001]
  • [Cites] J Urol. 1967 Jul;98(1):108-10 [6067877.001]
  • [Cites] Br J Ind Med. 1972 Apr;29(2):188-95 [5063206.001]
  • [Cites] Acta Derm Venereol. 1974;54(6):471-4 [4140663.001]
  • [Cites] Ann N Y Acad Sci. 1976;271:138-42 [1069495.001]
  • [Cites] J Urol. 1977 Jun;117(6):741-5 [559784.001]
  • [Cites] Urology. 1982 Mar;19(3):269-74 [7064253.001]
  • [Cites] Cancer. 1984 Aug 1;54(3):596-601 [6733690.001]
  • [Cites] Br J Ind Med. 1984 Nov;41(4):437-44 [6498107.001]
  • [Cites] Cancer. 1985 Feb 1;55(3):666-71 [3965115.001]
  • [Cites] Comput Programs Biomed. 1985;19(2-3):197-207 [3839736.001]
  • [Cites] Am J Public Health. 1989 Nov;79(11):1513-5 [2817163.001]
  • [Cites] Br J Ind Med. 1989 Jun;46(6):430-1 [2818983.001]
  • [Cites] Br J Urol. 1991 Oct;68(4):414-7 [1933164.001]
  • [Cites] J Urol. 1991 Nov;146(5):1299-304 [1942281.001]
  • [Cites] Cancer Causes Control. 1992 Jan;3(1):91-3 [1536920.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2759-64 [8194017.001]
  • [Cites] Occup Med (Lond). 1996 Feb;46(1):69-70 [8672799.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):108-13 [10087941.001]
  • [Cites] AMA Arch Ind Health. 1959 May;19(5):530-9 [13636468.001]
  • [Cites] Br J Ind Med. 1972 Oct;29(4):394-406 [15625750.001]
  • [Cites] Ned Tijdschr Geneeskd. 2006 May 20;150(20):1108-15 [16756222.001]
  • [Cites] Arch Dermatol. 2000 Dec;136(12):1524-30 [11115165.001]
  • (PMID = 20877361.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2990603
  •  go-up   go-down


12. Cohen JL: Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2010 Jun;3(6):39-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratosis treatment as a key component of preventive strategies for nonmelanoma skin cancer.
  • Actinic keratosis, the result of chronic sun damage to the skin, is closely linked to nonmelanoma skin cancer, both histologically and pathophysiologically.
  • Clinical evidence shows that not only does actinic keratosis have the potential to progress and transform into nonmelanoma skin cancer, but it also may in fact be an early stage of cancer.
  • The treatment of actinic keratosis is evolving from a "treat-as-you-go" strategy to a more preventive approach to curtail the potential emergence of nonmelanoma skin cancer.
  • As the interrelationship between actinic keratosis and nonmelanoma skin cancer, squamous cell carcinoma, and basal cell carcinoma continues to strengthen, treating actinic keratosis as part of a preventive strategy to reduce nonmelanoma skin cancer is coming to the forefront.
  • The following review of the relationship between actinic keratosis and nonmelanoma skin cancer discusses the rationale for early actinic keratosis treatment to prevent or reduce nonmelanoma skin cancer occurrence.

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 2004 Dec;74(6 Suppl):9-17 [15666897.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):8-13 [12353680.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] J Cutan Med Surg. 2002 May-Jun;6(3):207-9 [11951126.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85 [11880204.001]
  • [Cites] N Engl J Med. 2001 Mar 29;344(13):975-83 [11274625.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):149-56 [10620131.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):171-5 [19863513.001]
  • [Cites] Am J Pathol. 2008 May;172(5):1248-55 [18403589.001]
  • [Cites] Dermatol Surg. 2008 Jan;34(1):9-13; discussion 13-4 [18053057.001]
  • [Cites] Int J Dermatol. 2007 Sep;46(9):895-904 [17822489.001]
  • [Cites] Dermatol Surg. 2007 Sep;33(9):1099-101 [17760601.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):976-82 [16924046.001]
  • [Cites] Dermatol Surg. 2006 Aug;32(8):1045-9 [16918567.001]
  • [Cites] Arch Dermatol. 2006 Jun;142(6):729-35 [16785375.001]
  • [Cites] J Fam Pract. 2006 May;55(5):suppl 1-8 [16672155.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):542-4 [16482195.001]
  • [Cites] J Invest Dermatol. 2006 Mar;126(3):569-74 [16374480.001]
  • [Cites] Clin Transplant. 2005 Dec;19(6):726-34 [16313317.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):60-7 [15655143.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):28-33 [15842610.001]
  • [Cites] Cutis. 1999 Jun;63(6):348 [10388958.001]
  • [Cites] Int J Dermatol. 1998 Sep;37(9):677-81 [9762818.001]
  • [Cites] J Eur Acad Dermatol Venereol. 1998 Jan;10(1):42-7 [9552756.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):920-3 [9041154.001]
  • [Cites] J Invest Dermatol. 1994 Oct;103(4):461-8 [7930668.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):1933-8 [7636533.001]
  • [Cites] Arch Dermatol. 1991 Jul;127(7):1029-31 [2064402.001]
  • [Cites] N Engl J Med. 1988 Jun 23;318(25):1633-7 [3287161.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] J Am Acad Dermatol. 1986 Oct;15(4 Pt 2):829-35 [3534022.001]
  • [Cites] Br J Dermatol. 1986 Dec;115(6):649-55 [3801305.001]
  • [Cites] Br J Dermatol. 2004 Jul;151(1):196-200 [15270891.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):189-96 [15262304.001]
  • [Cites] Transplantation. 2004 Jan 15;77(1):115-21 [14724445.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):518-23 [15787821.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):759-65 [15681519.001]
  • [Cites] J Dermatolog Treat. 2003;14 Suppl 2:3-6 [14578092.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • (PMID = 20725550.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2921751
  •  go-up   go-down


13. Braga JC, Scope A, Klaz I, Mecca P, González S, Rabinovitz H, Marghoob AA: The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions. J Am Acad Dermatol; 2009 Aug;61(2):230-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions.
  • BACKGROUND: Solitary pink lesions often manifest nondescript clinical and dermatoscopic primary morphologic features.
  • The differential diagnosis for pink lesions tends, therefore, to be broad, ranging from inflammatory processes to malignancy.
  • OBJECTIVE: We sought to demonstrate the use of RCM as an adjunct to the bedside diagnosis of pink lesions.
  • METHODS: We describe a series of patients with clinically and dermatoscopically equivocal pink lesions for which RCM examination allowed for a rapid and accurate diagnosis.
  • RESULTS: Lesions included basal cell carcinoma, squamous cell carcinoma, amelanotic melanoma, and inflamed seborrheic keratosis.
  • In the cases presented RCM allowed for a rapid and accurate noninvasive diagnosis.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Keratosis, Actinic / pathology. Melanoma / pathology. Microscopy, Confocal. Pigmentation Disorders / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Dermoscopy / methods. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sampling Studies. Sensitivity and Specificity


14. Kumar R: Clinicopathologic study of malignant eyelid tumours. Clin Exp Optom; 2010 Jul;93(4):224-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic study of malignant eyelid tumours.
  • BACKGROUND: Early diagnosis of malignancy of eyelids can save the visual system from metastasis.
  • RESULTS: A total of 37 malignant eyelid tumours were seen.
  • Sebaceous gland carcinoma was the commonest (40.5 per cent) finding, followed by squamous cell carcinoma (27 per cent), basal cell carcinoma (24.3 per cent), basosquamous carcinoma (5.4 per cent) and malignant melanoma (2.7 per cent).
  • CONCLUSIONS: As the most common tumour in the region, sebaceous gland carcinoma might be due to geographical and environmental variations and requires immediate consultation and histopathologic diagnosis of lid lesions above 40 years of age for treatment strategies.
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Carcinoma / epidemiology. Carcinoma / pathology. Carcinoma, Basosquamous / epidemiology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Child. Female. Humans. Incidence. Male. Middle Aged. Nepal / epidemiology. Sebaceous Gland Neoplasms / epidemiology. Sebaceous Gland Neoplasms / pathology. Sex Distribution. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20465547.001).
  • [ISSN] 1444-0938
  • [Journal-full-title] Clinical & experimental optometry
  • [ISO-abbreviation] Clin Exp Optom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


15. Kimball KJ, Straughn JM, Conner MG, Kirby TO: Recurrent basosquamous cell carcinoma of the vulva. Gynecol Oncol; 2006 Aug;102(2):400-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent basosquamous cell carcinoma of the vulva.
  • BACKGROUND: Basosquamous cell carcinoma (BSC) of the vulva is a rare entity with interesting prognostic and therapeutic implications.
  • CONCLUSION: BSC is a rare disorder of the vulva.
  • The metastatic potential of this tumor is not fully understood, but likely is intermediate between squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Carcinoma, Basosquamous / surgery. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Vulvar Neoplasms / pathology. Vulvar Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16624392.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Ullah T, Gurwood AS, Myers MD: Ocular metastasis of cutaneous malignant melanoma. Optometry; 2009 Oct;80(10):572-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ocular metastasis of cutaneous malignant melanoma.
  • Patients at greatest risk often have disseminated metastases in the setting of advanced disease.
  • Because the prognosis for orbital metastatic disease is poor, emphasis must be placed on early detection and prevention.
  • Although cutaneous malignancies include basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma, the majority of cases that result in metastasis, ocular morbidity, and mortality are from sebaceous cell carcinoma and malignant melanoma.
  • Her systemic medical history was significant for the diagnosis of a cutaneous malignant melanoma.
  • Magnetic resonance imaging confirmed the diagnosis of metastatic lesions involving structures of the left orbit ultimately causing reduced visual ability.
  • Although orbital metastasis is considered a terminal finding in these cases, timely diagnosis enables, while limited, the best options for management.
  • [MeSH-major] Melanoma / secondary. Orbital Neoplasms / secondary. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Ocular melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19801341.001).
  • [ISSN] 1558-1527
  • [Journal-full-title] Optometry (St. Louis, Mo.)
  • [ISO-abbreviation] Optometry
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Lee YH, Ghohestani RF: BURNS and ERUPTS: novel mnemonics for detection of squamous cell carcinoma and basal cell carcinoma. Eur J Dermatol; 2010 Nov-Dec;20(6):829-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BURNS and ERUPTS: novel mnemonics for detection of squamous cell carcinoma and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Reminder Systems. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20974557.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] France
  •  go-up   go-down


18. Chren MM, Sahay AP, Bertenthal DS, Sen S, Landefeld CS: Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol; 2007 Jun;127(6):1351-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality-of-life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma.
  • Quality of life is an important treatment outcome for conditions that are rarely fatal, such as cutaneous basal cell carcinoma and squamous cell carcinoma (typically called nonmelanoma skin cancer (NMSC)).
  • The main outcome was tumor-related quality of life 1 to 2 years after therapy, measured with the 16-item version of Skindex, a validated measure.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Basal Cell / surgery. Quality of Life. Skin Neoplasms / psychology. Skin Neoplasms / surgery
  • [MeSH-minor] Aged. Aged, 80 and over. Carcinoma, Squamous Cell / psychology. Carcinoma, Squamous Cell / surgery. Emotions. Female. Follow-Up Studies. Health Status Indicators. Humans. Male. Middle Aged. Mohs Surgery. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301830.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K02 AR 02203-01
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


19. Galloway TJ, Morris CG, Mancuso AA, Amdur RJ, Mendenhall WM: Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion. Cancer; 2005 Mar 15;103(6):1254-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of radiographic findings on prognosis for skin carcinoma with clinical perineural invasion.
  • BACKGROUND: The objective of the current study was to correlate pretreatment computed tomography and magnetic resonance imaging studies with outcomes for patients with squamous or basal cell carcinoma of the skin and clinical perineural invasion.
  • Patients were stratified as follows: imaging negative, 10 patients; minimal or moderate peripheral disease, 14 patients; and central and/or macroscopic disease, 21 patients.
  • RESULTS: The 5-year local control rates were as follows: imaging negative, 76%; minimal or moderate peripheral disease, 57%; and central and/or macroscopic disease, 25%.
  • The 5-year absolute and cause-specific survival rates were as follows: imaging negative, 90% and 100%, respectively; minimal or moderate peripheral disease, 50% and 56%, respectively; and central and/or macroscopic disease, 58% and 61%, respectively.
  • Patients who had imaging-positive minimal or moderate peripheral disease had a better local control rate but a similar survival rate compared with patients who had central and/or macroscopic disease.
  • [MeSH-major] Carcinoma, Basal Cell / radiography. Carcinoma, Squamous Cell / radiography. Neoplasm Invasiveness / pathology. Skin Neoplasms / radiography
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Assessment. Sampling Studies. Sensitivity and Specificity. Sex Factors. Survival Analysis. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693020.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


21. Karagas MR, Waterboer T, Li Z, Nelson HH, Michael KM, Bavinck JN, Perry AE, Spencer SK, Daling J, Green AC, Pawlita M, New Hampshire Skin Cancer Study Group: Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study. BMJ; 2010 Jul 08;341:c2986
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genus beta human papillomaviruses and incidence of basal cell and squamous cell carcinomas of skin: population based case-control study.
  • OBJECTIVE: To investigate the association between genus beta human papillomaviruses and the incidence of non-melanocytic skin cancer in the general population.
  • PARTICIPANTS: 2366 skin cancer cases and controls from the general population aged 25 to 74 years (663 squamous cell carcinoma, 898 basal cell carcinoma, 805 controls), with plasma samples tested for L1 antibodies to 16 genus beta human papillomaviruses by multiplex serology.
  • MAIN OUTCOME MEASURES: Odds ratios for squamous cell carcinoma and basal cell carcinoma associated with seropositivity to beta human papillomaviruses.
  • RESULTS: Squamous cell carcinoma, but not basal cell carcinoma, cases had a higher prevalence of each of the individual beta human papillomaviruses assayed compared with controls.
  • The odds ratios for squamous cell carcinoma increased with the number of beta types positive (odds ratio for one type positive 0.99 (95% confidence interval 0.74 to 1.33); two to three types positive 1.44 (1.03 to 2.01); four to eight types positive 1.51 (1.03 to 2.20); more than eight types positive 1.71 (1.12 to 2.62); P for trend (categorical)<0.001; P for trend (continuous)=0.003).
  • CONCLUSIONS: These findings support a relation between genus beta human papillomavirus infection and the incidence of squamous cell carcinoma of the skin in the general population, as well as potential enhancement of risk by immunosuppression.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Jan;142(1):103-9 [10651702.001]
  • [Cites] J Virol. 2008 Nov;82(21):10408-17 [18715924.001]
  • [Cites] J Immunol Methods. 2001 Jul 1;253(1-2):153-62 [11384677.001]
  • [Cites] Br J Cancer. 2001 Sep 1;85(5):683-6 [11531252.001]
  • [Cites] J Virol Methods. 2002 Oct;106(1):61-70 [12367730.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):890-4 [12873884.001]
  • [Cites] J Natl Cancer Inst. 2004 May 5;96(9):709-11 [15126608.001]
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] Am J Epidemiol. 1976 Feb;103(2):226-35 [1251836.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] J Virol. 1990 Sep;64(9):4399-406 [2166821.001]
  • [Cites] N Engl J Med. 1990 Sep 20;323(12):789-95 [2202901.001]
  • [Cites] Int J Cancer. 1991 Jul 9;48(5):650-62 [2071226.001]
  • [Cites] Cancer Causes Control. 1994 Jul;5(4):367-92 [8080949.001]
  • [Cites] Transplantation. 1996 Mar 15;61(5):715-21 [8607173.001]
  • [Cites] J Natl Cancer Inst. 1996 Dec 18;88(24):1848-53 [8961975.001]
  • [Cites] J Invest Dermatol. 1998 Oct;111(4):696-701 [9764856.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Clin Chem. 2005 Oct;51(10):1845-53 [16099939.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):529-35 [16537712.001]
  • [Cites] J Natl Cancer Inst. 2006 Mar 15;98(6):389-95 [16537831.001]
  • [Cites] Am J Epidemiol. 2007 Mar 15;165(6):719-26 [17204514.001]
  • [Cites] Dis Markers. 2007;23(4):247-59 [17627060.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1862-8 [17565742.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):189-95 [18199724.001]
  • [Cites] PLoS Pathog. 2008 Jun;4(6):e1000091 [18566657.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1731-8 [18628425.001]
  • [Cites] Br J Dermatol. 2008 Aug;159(2):457-9 [18503604.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • (PMID = 20616098.001).
  • [ISSN] 1756-1833
  • [Journal-full-title] BMJ (Clinical research ed.)
  • [ISO-abbreviation] BMJ
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / P30 CA023108; United States / NCI NIH HHS / CA / CA57494; United States / NCI NIH HHS / CA / R01 CA118443; United States / NCI NIH HHS / CA / CA118443
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Viral
  • [Other-IDs] NLM/ PMC2900549
  • [Investigator] Anderson DR; Averill RW; Aversa AJ; Brady S; Bairstow BA; Baughman RD; Blasik LG; Campbell J; Carroll C; Chapman MS; Clendenning WE; Collison DW; Crespo JL; Danby FW; Del Guidice SM; Dimond RL; Dinulos JG; Draper WS; Finkle JP; Fisher J; Fournier J; Frank WE; Fromer JL; Goldberg NC; Goldminz D; Gordon R; Greenstein DS; Habif TP; Hammer C; Hokanson T; Joselow SA; Lewis G; Lichter MD; Liranzo MO; Margesson L; Mittleman MA; Peraza J; Posnick RB; Pringle WM; Quitadamo M; Reohr PB; Reynolds NC; Ryan A; Sands P; Schwartz ME; Seymour G; Sherman LD; Sisto JA; Spencer SK; Starke JC; Stewart MI; Sullivan S; Thyresson NH; Truhan AP; Tye MJ; Watson J; Waterson KW; Willer R; Zug K
  •  go-up   go-down


22. Perkins W: Who should have Mohs micrographic surgery? Curr Opin Otolaryngol Head Neck Surg; 2010 Aug;18(4):283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE OF REVIEW: To review the indications for Mohs micrographic surgery in skin cancer particularly with relationship to tumours of the head and neck and any recent developments which may influence those indications in the near future.
  • RECENT FINDINGS: There is increasing evidence to support the use of Mohs micrographic surgery in the treatment of recurrent and primary basal cell carcinoma and in squamous cell carcinoma, particularly when there is evidence of perineural invasion.
  • [MeSH-major] Mohs Surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Decision Making. Dermatofibrosarcoma / surgery. Histiocytoma, Benign Fibrous / surgery. Humans. Melanoma / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20613530.001).
  • [ISSN] 1531-6998
  • [Journal-full-title] Current opinion in otolaryngology & head and neck surgery
  • [ISO-abbreviation] Curr Opin Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


23. Adenis JP, Sabatier A, Robert PY: [Tumors of the eyelids in the elderly]. J Fr Ophtalmol; 2006 Jun;29(6):687-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The clinical aspect of tumors of the eyelids is polymorphous; however, the most frequent are benign tumors such as papillomas, basal cell carcinoma, squamous cell carcinoma, meibomian gland carcinoma, and melanomas.
  • An important step in the management of the malignant types is to try to establish clear margins through histopathologic techniques: the Mohs technique, the rapid fixation technique, and the frozen section method are the most frequent technical tools used today.
  • For the most malignant tumors such as malignant melanoma and Merkel cell tumor, lymph sentinel biopsy is a recent, valuable tool, but its benefit needs to be confirmed in large series.
  • [MeSH-major] Eyelid Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885901.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 13
  •  go-up   go-down


24. Hargis AM, Baldessari AE, Walder EJ: Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease. Vet Dermatol; 2008 Feb;19(1):31-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraepidermal adenocarcinoma in the perianal skin of two cats, a condition resembling human extramammary Paget's disease.
  • In humans, mammary and extramammary Paget's disease is an uncommon to rare manifestation of intraepidermal adenocarcinoma arising from simple epithelium, usually glandular in origin.
  • This report describes two cats with lesions in perianal skin consisting of atypical intraepidermal neoplastic cells.
  • Differential diagnoses included intraepidermal adenocarcinoma, in situ squamous or basal cell carcinoma, junctional amelanotic melanoma, and epitheliotropic tumours of histiocytic or lymphocytic origin.
  • The keratinocytes and basal cells were negative for CK8/18.
  • In one cat the clinical lesions consisted of a pruritic erythematous eruption surrounding the anus.
  • The clinical features, histological appearance, and immunohistochemical staining of the skin lesions were consistent with those described for human perianal extramammary Paget's disease.
  • [MeSH-major] Adenocarcinoma / veterinary. Cat Diseases / diagnosis. Perineum / pathology. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Diagnosis, Differential. Female. Humans. Paget Disease, Extramammary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18177290.001).
  • [ISSN] 0959-4493
  • [Journal-full-title] Veterinary dermatology
  • [ISO-abbreviation] Vet. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


25. Perrotto J, Glick B: Lower extremity malignancies masquerading as ulcers. Ostomy Wound Manage; 2006 Oct;52(10):46-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous malignancies that may masquerade as ulcers include nodulo-ulcerative basal cell carcinoma, squamous cell carcinoma, keratoacanthoma, nodular melanoma, tumor stage mycosis fungoides, lymphomatoid granulomatosis, lymphomatoid papulosis, angiosarcoma, and cutaneous metastases from internal malignancy.
  • [MeSH-major] Neoplasms / diagnosis. Skin Ulcer / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17041254.001).
  • [ISSN] 0889-5899
  • [Journal-full-title] Ostomy/wound management
  • [ISO-abbreviation] Ostomy Wound Manage
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Altrabulsi B, Carrizo F, Luna MA: Spindle basaloid squamous carcinoma of the upper aerodigestive tract: immunohistochemical and clinicopathological study of three cases. Ann Diagn Pathol; 2006 Jun;10(3):149-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spindle basaloid squamous carcinoma of the upper aerodigestive tract: immunohistochemical and clinicopathological study of three cases.
  • We describe the clinicopathological and immunohistochemical features of three spindle (sarcomatoid) basaloid squamous carcinomas in three men aged 73, 69, and 59 years with a history of tobacco and alcohol abuse.
  • Histologically, they were composed of conventional basaloid squamous carcinomas with extensive malignant spindle cell proliferation, comprising more than 50% of the tumor.
  • One case in addition expressed CD99 and Bcl-2 and was originally diagnosed as monophasic synovial sarcoma; however, a subsequent biopsy disclosed basaloid squamous cell carcinoma with sarcomatoid stroma.
  • The patients were alive 14 (case patient 1), 10 (case patient 2), and 8 (case patient 3) months after diagnosis.
  • In the absence of evidence from immunohistochemical or electron microscopy studies, a polypoid malignant spindle cell tumor of a mucosal surface of the upper aerodigestive tract should be considered a sarcomatoid carcinoma until proven otherwise.
  • The type of epithelial component would determine the subtype of sarcomatoid carcinoma.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Hypopharyngeal Neoplasms / pathology. Hypopharynx / pathology. Maxillary Neoplasms / pathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. Laryngectomy. Male. Maxilla / surgery. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730309.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


27. Gremmel T, Wild S, Schuller W, Kürten V, Dietz K, Krutmann J, Berneburg M: Six genes associated with the clinical phenotypes of individuals with deficient and proficient DNA repair. Transl Oncogenomics; 2008 Feb 10;3:1-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Xeroderma pigmentosum (XP) is a genetic disorder characterised by hypo-/hyperpigmentation, increased sensitivity to ultraviolet (UV)-radiation and an up to 2000-fold increased skin cancer risk.
  • This defect accounts for their mutator phenotype but does not predict their increased skin cancer risk.
  • Therefore, we carried out array analysis to measure the expression of more than 1000 genes after UVB-irradiation in XP cells from three complementation groups with different clinical severity (XP-A, XP-D, XP-F) as well as from patients with normal DNA repair but increased skin cancer risk (≥2 basal or squamous cell carcinoma at age <40yrs).
  • Genes identified in XP cells could be confirmed in cells from patients with no known DNA repair defects but increased skin cancer risk.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 1980 Jan;69(1):177-90 [6987495.001]
  • [Cites] Cancer Res. 1989 Nov 1;49(21):6162-3 [2676158.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] Science. 2000 Sep 8;289(5485):1670-2 [11001727.001]
  • [Cites] Adv Genet. 2001;43:71-102 [11037299.001]
  • [Cites] Genes Dev. 1999 Apr 1;13(7):768-85 [10197977.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):431-8 [10667598.001]
  • [Cites] EMBO J. 2000 Mar 1;19(5):1157-66 [10698956.001]
  • [Cites] J Photochem Photobiol B. 2000 Feb;54(2-3):87-93 [10836536.001]
  • [Cites] Nature. 2000 Aug 3;406(6795):532-5 [10952316.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4797-808 [11406555.001]
  • [Cites] Mol Cell. 2001 Jul;8(1):213-24 [11511374.001]
  • [Cites] Nat Cell Biol. 2002 Jan;4(1):26-31 [11780128.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2923-8 [12019173.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3759-65 [12097286.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1635-46 [12820975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5 [12883005.001]
  • [Cites] Mutat Res. 2003 Nov;544(2-3):107-14 [14644313.001]
  • [Cites] J Dermatol Sci. 2004 May;34(3):185-94 [15113588.001]
  • [Cites] FASEB J. 2004 Oct;18(13):1559-61 [15289447.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6511-23 [15374962.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1359-74 [15608684.001]
  • [Cites] J Exp Med. 2005 Jan 17;201(2):173-9 [15657287.001]
  • [Cites] Mutat Res. 2005 Apr 1;571(1-2):43-56 [15748637.001]
  • [Cites] Photochem Photobiol Sci. 2002 Sep;1(9):656-64 [12665302.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jul 11;306(4):1026-36 [12821146.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6837-41 [9192652.001]
  • (PMID = 21566739.001).
  • [Journal-full-title] Translational oncogenomics
  • [ISO-abbreviation] Transl Oncogenomics
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3022359
  • [Keywords] NOTNLM ; DNA repair / array analysis / basal cell carcinoma / skin cancer risk / squamous cell carcinoma / xeroderma pigmentosum
  •  go-up   go-down


28. Maroldi R, Farina D, Borghesi A, Marconi A, Gatti E: Perineural tumor spread. Neuroimaging Clin N Am; 2008 May;18(2):413-29, xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural tumor spread.
  • Perineural spread (PNS) refers to the extent of tumor cells or other nonneoplastic lesions along the tissues of the nerve sheath, its overall incidence ranges from 2.5% to 5%.
  • PNS is more frequently associated with carcinoma arising from minor or major salivary glands (more often adenoid cystic carcinoma), mucosal or cutaneous squamous cell carcinoma, basal cell carcinoma, melanoma, lymphoma, and sarcoma.
  • Therefore, radiologists must be aware of the relevant cranial nerve anatomy and thoroughly scrutinize not only the nerves close to the primary tumor site but also the whole neural pathways that can be accessed by PNS.
  • Equally critical is knowledge of the radiologic appearance of perineural tumor extension and the best imaging strategies to detect PNS.
  • [MeSH-major] Cranial Nerve Neoplasms / diagnosis. Cranial Nerve Neoplasms / secondary. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / secondary
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18466839.001).
  • [ISSN] 1052-5149
  • [Journal-full-title] Neuroimaging clinics of North America
  • [ISO-abbreviation] Neuroimaging Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 60
  •  go-up   go-down


29. Park K, Lee JH: Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation. Oncol Rep; 2009 Mar;21(3):689-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation.
  • There is considerable evidence that the excessive ultraviolet radiation B (UVB) from sunlight is implicated in skin damage, ultimately inducing the death of keratinocytes.
  • If the apoptotic pathway does not work properly, the damaged cells have a chance to transform into a carcinoma, such as basal cell carcinoma or squamous cell carcinoma of the skin.
  • To develop a strategy of inducing apoptosis of skin cancer cells, the current study was performed to investigate the apoptotic pathway, especially focused on Bcl2 family proteins, in curcumin or UVB-treated basal cell carcinoma cell lines.
  • Our data demonstrated that the expression of Bcl-XL protein was decreased by proteasome-mediated degradation prior to change of mRNA level in UVB-induced apoptotic basal cell carcinoma cell lines, thereby these results will offer fundamental information to develop a strategy of inducing apoptosis of skin cancer cells.
  • [MeSH-major] Apoptosis / radiation effects. Carcinoma, Basal Cell / metabolism. Proteasome Endopeptidase Complex / radiation effects. bcl-X Protein / radiation effects
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cell Proliferation / radiation effects. Curcumin / pharmacology. DNA Fragmentation. Gene Expression / radiation effects. Humans. Reverse Transcriptase Polymerase Chain Reaction. Ultraviolet Rays. bcl-2-Associated X Protein / radiation effects. bcl-Associated Death Protein / radiation effects

  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19212627.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / bcl-2-Associated X Protein; 0 / bcl-Associated Death Protein; 0 / bcl-X Protein; EC 3.4.25.1 / Proteasome Endopeptidase Complex; IT942ZTH98 / Curcumin
  •  go-up   go-down


30. Meslemani DM, Jones L: An unusual presentation of nasal type NK/T-cell lymphoma of the nose. Laryngoscope; 2010;120 Suppl 4:S167
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of nasal type NK/T-cell lymphoma of the nose.
  • OBJECTIVES: Case report of a male with a rare nasal type NK/T cell lymphoma that presented as an aggressive nasal infection superimposed with squamous and basal cell carcinoma.
  • A review of the diagnosis, management, and prognosis nasal type NK/T cell lymphoma will be presented.
  • METHODS: Review of the literature for cases of nasal type NK/T cell lymphoma, with particular attention to its presentations.
  • RESULTS: Differential diagnosis includes aggressive infection of the nasal skin, carcinoma, and lymphoma.
  • CONCLUSION: No cases in the literature of NK/T cell lymphoma have been reported that presented with an aggressive infection with initial biopsies that revealed squamous cell and basal cell carcinoma, which led to surgical management and a definitive diagnosis of Nasal type NK/T cell lymphoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Male. Middle Aged. Rhinitis / pathology. Sinusitis / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21225765.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


31. Panizzon RG: [Dermatologic radiotherapy]. Hautarzt; 2007 Aug;58(8):701-10, quiz 711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Another important parameter is the half-value depth which should correspond to the depth of the tumor below the skin surface.
  • In this way the skin is not over-exposed to radiation treatment.
  • Indications for radiotherapy of malignant skin tumors include basal cell carcinoma, squamous cell carcinoma, severe actinic keratoses, lentigo maligna, lentigo maligna melanoma, Merkel cell carcinoma, and Kaposi sarcoma, as well as T- and B-cell lymphomas.
  • Most patients with malignant skin tumors require life-long monitoring after radiotherapy.
  • [MeSH-major] Precancerous Conditions / radiotherapy. Skin Diseases / radiotherapy. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Eczema / radiotherapy. Humans. Keloid / radiotherapy. Lymphoma, B-Cell / radiotherapy. Lymphoma, T-Cell, Cutaneous / radiotherapy. Palliative Care. Psoriasis / radiotherapy. Radiotherapy Dosage. Sarcoma, Kaposi / radiotherapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639284.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


32. Russo GG: Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments. Clin Dermatol; 2005 Nov-Dec;23(6):581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Actinic keratoses, basal cell carcinoma, and squamous cell carcinoma: uncommon treatments.
  • This contribution will discuss the treatment of actinic keratoses, basal cell carcinomas, and squamous cell carcinoma using methods that are not routinely established but have been used for a long period.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / therapy. Keratosis / drug therapy. Photosensitivity Disorders / therapy. Skin Neoplasms / therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. COLCHICINE .
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325066.001).
  • [ISSN] 0738-081X
  • [Journal-full-title] Clinics in dermatology
  • [ISO-abbreviation] Clin. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 144O8QL0L1 / Diclofenac; 9004-61-9 / Hyaluronic Acid; SML2Y3J35T / Colchicine
  • [Number-of-references] 53
  •  go-up   go-down


33. Norval M, Cullen AP, de Gruijl FR, Longstreth J, Takizawa Y, Lucas RM, Noonan FP, van der Leun JC: The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochem Photobiol Sci; 2007 Mar;6(3):232-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Solar UVR has many harmful and some beneficial effects on individuals and, in this review, information mainly published since the previous report in 2003 (F. R. de Gruijl, J.
  • Takizawa and J. C. van der Leun, Photochem. Photobiol.
  • Studying how UV-B interacts with the surface and internal structures of the eye has led to a further understanding of the location and pathogenesis of a number of ocular diseases, including pterygium and cataract.
  • The skin is also exposed directly to solar UVR, and the development of skin cancer is the main adverse health outcome of excessive UVR exposure.
  • Skin cancer is the most common form of malignancy amongst fair-skinned people, and its incidence has increased markedly in recent decades.
  • Several of the genetic factors affecting susceptibility to the development of squamous cell carcinoma, basal cell carcinoma and melanoma have been identified.
  • Exposure to solar UVR down-regulates immune responses, in the skin and systemically, by a combination of mechanisms including the generation of particularly potent subsets of T regulatory cells.
  • Such immunosuppression is known to be a crucial factor in the generation of skin cancers.
  • Various strategies that can be adopted by the individual to protect against excessive exposure of the eye or the skin to sunlight are suggested.
  • [MeSH-minor] Animals. Eye / metabolism. Eye / radiation effects. Humans. Skin / metabolism. Skin / radiation effects. Vitamin D / metabolism


34. Anand BS, Verstovsek G, Cole G: Tubulovillous adenoma of anal canal: a case report. World J Gastroenterol; 2006 Mar 21;12(11):1780-1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors arising from the anal canal are usually of epithelial origin and are mostly squamous cell carcinoma or basal cell carcinoma.
  • We present a case of benign anal adenomas arising from the anus, an extremely rare diagnosis.
  • Microscopic examination revealed a tubulovillus adenoma with no areas of high grade dysplasia or malignant transformation.
  • The squamocolumnar junction was visible at the edges of the lesion confirming the anal origin of the tumor.
  • [MeSH-major] Adenoma, Villous / diagnosis. Anus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Anal Canal / pathology. Cell Transformation, Neoplastic. Humans. Male

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] J Clin Pathol. 2005 Feb;58(2):217-9 [15677547.001]
  • [Cites] Br J Surg. 1995 Dec;82(12):1634 [8548224.001]
  • (PMID = 16586552.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4124358
  •  go-up   go-down


35. Qureshi AA, Laden F, Colditz GA, Hunter DJ: Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma. Arch Intern Med; 2008 Mar 10;168(5):501-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Geographic variation and risk of skin cancer in US women. Differences between melanoma, squamous cell carcinoma, and basal cell carcinoma.
  • BACKGROUND: Occurrences of melanoma, squamous cell carcinoma (SCC), and basal cell carcinoma (BCC) have been associated with varying geography.
  • Our goal was to evaluate differences in risk of these skin cancers according to residence at varying UV indices at 3 time points.
  • The outcome measure was diagnosis of melanoma, SCC, or BCC.
  • RESULTS: During the 18-year study, 420 cases of melanoma, 863 cases of SCC, and 8215 cases of BCC occurred.
  • Although elevated, the age-adjusted risk of BCC at 30 years of age associated with residence in these states was substantially less.
  • CONCLUSIONS: The risk of SCC is independently affected by residence in locations with medium and high UV indices; the gradient of risk is weaker for BCC; and the risk of melanoma does not change significantly across this gradient.


36. Downs N, Parisi A: Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma. Photochem Photobiol Sci; 2009 Aug;8(8):1195-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Measurements of the anatomical distribution of erythemal ultraviolet: a study comparing exposure distribution to the site incidence of solar keratoses, basal cell carcinoma and squamous cell carcinoma.
  • The UV exposures were compared with existing data detailing the anatomical distribution of basal cell carcinoma (BCC), squamous cell carcinoma (SCC) and solar keratoses (SK).
  • Surface UV exposures to unprotected skin surfaces have been presented for each of the face, neck, arm, hand and leg assessing a total of 1453 body sites (2491 measurements).
  • Further analysis with existing facial BCC and SK density data did not however show a direct relationship with the measured UV exposures highlighting the importance of other factors influencing the causation and localisation of facial NMSC.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Keratosis / epidemiology. Skin / pathology. Ultraviolet Rays

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639123.001).
  • [ISSN] 1474-905X
  • [Journal-full-title] Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology
  • [ISO-abbreviation] Photochem. Photobiol. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


37. Bäckvall H, Asplund A, Gustafsson A, Sivertsson A, Lundeberg J, Ponten F: Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. Mutat Res; 2005 Apr 1;571(1-2):65-79
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma.
  • Skin cancer provides an advantageous model for studying the development of cancer.
  • Detectable lesions occur early during tumor progression, facilitating molecular analysis of the cell populations from both preneoplastic and neoplastic lesions.
  • Alterations of the p53 tumor suppressor gene are very common in non-melanoma skin cancer, and dysregulation of p53 pathways appear to be an early event in the tumor development.
  • A high frequency of epidermal p53 clones has been detected in chronically sun-exposed skin.
  • The abundance of clones containing p53 mutated keratinocytes adjacent to basal cell (BCC) and squamous cell carcinoma (SCC) suggests a role in human skin carcinogenesis.
  • Microdissection-based studies have also shown that different parts of individual BCC tumors can share a common p53 mutation yet differ with respect to additional alterations within the p53 gene, consistent with subclonal development within tumors.
  • Here, we present examples of using well-defined cell populations, including single cells, from complex tissue in combination with molecular tools to reveal features involved in skin carcinogenesis.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Genetic Heterogeneity. Skin Neoplasms / genetics


38. Schulman JM, Fisher DE: Indoor ultraviolet tanning and skin cancer: health risks and opportunities. Curr Opin Oncol; 2009 Mar;21(2):144-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indoor ultraviolet tanning and skin cancer: health risks and opportunities.
  • PURPOSE OF REVIEW: Skin cancer incidence is higher than that of any other human malignancy, and yet one of its root causes [ultraviolet (UV) radiation] is perhaps better understood than any other human carcinogen.
  • The roles of UV radiation exposure and indoor tanning behaviors on skin cancer risk are explored here.
  • RECENT FINDINGS: Studies from the past several years have shown a significant association between ever-use of an indoor tanning facility and an increased risk of basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • The association between indoor tanning and skin cancer is particularly strong among those who first used a tanning facility in early adulthood.
  • Elevated vitamin D levels have been suggested to protect against various internal malignancies and other disease states, but sources of vitamin D that do not require UV exposure are easily available.
  • SUMMARY: Although additional research is needed to understand fully the relationship between UV and skin cancer, it is already clear that indoor tanning bed use represents an avoidable risk factor for melanoma and nonmelanoma skin cancer - both of which may be lethal.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Photochem Photobiol B. 2001 Oct;63(1-3):88-102 [11684456.001]
  • [Cites] Health Policy. 2009 Mar;89(3):303-11 [18760857.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10124-8 [1946433.001]
  • [Cites] Nat Genet. 1995 Nov;11(3):328-30 [7581459.001]
  • [Cites] J Investig Dermatol Symp Proc. 1996 Apr;1(2):136-42 [9627707.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(1):45-60 [15617990.001]
  • [Cites] Cancer Causes Control. 2005 Mar;16(2):83-95 [15868450.001]
  • [Cites] J Am Acad Dermatol. 2006 Apr;54(4):589-96 [16546579.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 12;103(37):13765-70 [16954188.001]
  • [Cites] Nature. 2006 Sep 21;443(7109):340-4 [16988713.001]
  • [Cites] J Am Acad Dermatol. 2006 Dec;55(6):962-7 [17097392.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1116-22 [17131335.001]
  • [Cites] J Am Acad Dermatol. 2007 Mar;56(3):375-9 [17257709.001]
  • [Cites] Cell. 2007 Mar 9;128(5):853-64 [17350573.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2445-51 [17311289.001]
  • [Cites] Arch Dermatol. 2007 Apr;143(4):529-32 [17438188.001]
  • [Cites] J Am Acad Dermatol. 2007 May;56(5):774-80 [17276543.001]
  • [Cites] Arch Intern Med. 2007 Jun 11;167(11):1159-65 [17563024.001]
  • [Cites] J Natl Cancer Inst. 2007 Jul 18;99(14):1120-9 [17623801.001]
  • [Cites] Br J Dermatol. 2007 Aug;157(2):350-6 [17650177.001]
  • [Cites] Cancer Causes Control. 2007 Nov;18(9):989-99 [17653830.001]
  • [Cites] PLoS Med. 2007 Mar;4(3):e103 [17388667.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2388-95 [17686627.001]
  • [Cites] Int J Cancer. 2008 Jan 1;122(1):144-54 [17708556.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1594-602 [17971526.001]
  • [Cites] Int J Dermatol. 2007 Dec;46(12):1253-7 [18173518.001]
  • [Cites] Am J Health Behav. 2008 Sep-Oct;32(5):451-64 [18241130.001]
  • [Cites] Photochem Photobiol. 2008 Mar-Apr;84(2):272-83 [18353168.001]
  • [Cites] Dermatol Surg. 2008 Apr;34(4):460-74 [18248469.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5):769-80 [18328594.001]
  • [Cites] Arch Dermatol. 2008 Apr;144(4):484-8 [18427042.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):796-804 [18505967.001]
  • [Cites] Cancer Causes Control. 2008 Sep;19(7):659-69 [18273687.001]
  • [Cites] Photochem Photobiol. 2008 Sep-Oct;84(5):1100-8 [18399922.001]
  • [Cites] Photochem Photobiol. 2008 Nov-Dec;84(6):1487-92 [18513233.001]
  • [Cites] J Natl Cancer Inst. 2002 Feb 6;94(3):224-6 [11830612.001]
  • (PMID = 19532016.001).
  • [ISSN] 1531-703X
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] ENG
  • [Grant] United States / CCR NIH HHS / RC / AR058469-01; United States / NIAMS NIH HHS / AR / R01 AR043369; United States / NIAMS NIH HHS / AR / RC1 AR058469; United States / NIAMS NIH HHS / AR / RC1 AR058469-01
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 37
  • [Other-IDs] NLM/ NIHMS202769; NLM/ PMC2913608
  •  go-up   go-down


39. Merté RL, Pfrommer S: [Definition of the success of the surgical treatment of palpebral tumours with respect to quality of life]. Klin Monbl Augenheilkd; 2010 Jul;227(7):582-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: The NEI-VFQ + was presented to a group of 73 patients (average age 71 years) after surgical treatment of malignant palpebral tumours (basal cell carcinoma, squamous cell carcinoma, melanoma).
  • CONCLUSIONS: The overall success of a particular surgical intervention to treat a malignant palpebral tumour depends not only on the expected minimisation of future health problems, including decreased visual function, but appears to depend strongly on the personal expectations of individual patients with respect to the aesthetic outcome.
  • Therefore in the case of a malignant palpebral tumour, it should be envisaged to plan a treatment strategy not only on the basis of the objective needs and limitations as seen by the surgeon, but also involving the patient's concern with all his/her expectations and fears in order to build up more mutual trust and to get a result that is satisfactory for the surgeon as well as for the patient.

  • MedlinePlus Health Information. consumer health - Corneal Disorders.
  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 20645231.001).
  • [ISSN] 1439-3999
  • [Journal-full-title] Klinische Monatsblätter für Augenheilkunde
  • [ISO-abbreviation] Klin Monbl Augenheilkd
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


40. Amini S, Viera MH, Valins W, Berman B: Nonsurgical innovations in the treatment of nonmelanoma skin cancer. J Clin Aesthet Dermatol; 2010 Jun;3(6):20-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonsurgical innovations in the treatment of nonmelanoma skin cancer.
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of cancer in the United States and represent 75 percent and 20 percent, respectively, of all nonmelanoma skin cancers.
  • Additional preventive measures include identifying high-risk individuals for early detection along with using agents, such as retinoids, that are effective in decreasing the risk of premalignant cells further developing into carcinomas.
  • Procedural modalities are currently the standard of treatment, but recent evidence has consistently shown that newer (nonsurgical) therapies, such as interferon, imiquimod, retinoids, and 5-fluorouracil, can be used effectively either as monotherapies or as adjuvants to those surgical modalities for the treatment of superficial nonmelanoma skin cancers and premalignant lesions.
  • Procedural modalities that have been evolving into important tools for the treatment of actinic keratosis and nonmelanoma skin cancers include photodynamic therapy and lasers.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nutr Cancer. 2008;60(3):325-30 [18444166.001]
  • [Cites] J Drugs Dermatol. 2008 Apr;7(4):405-8 [18459526.001]
  • [Cites] Expert Opin Biol Ther. 2008 Jun;8(6):829-38 [18476794.001]
  • [Cites] Br J Dermatol. 2008 Jul;159(1):205-10 [18476957.001]
  • [Cites] J Drugs Dermatol. 2008 May;7(5):483-5 [18505144.001]
  • [Cites] J Dermatolog Treat. 2008;19(3):159-63 [18569272.001]
  • [Cites] J Drugs Dermatol. 2008 Jul;7(7):669-73 [18664159.001]
  • [Cites] J Dtsch Dermatol Ges. 2009 Feb;7(2):128-33 [18808378.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):743-54 [18813320.001]
  • [Cites] J Am Acad Dermatol. 2009 Jan;60(1):59-62 [18937999.001]
  • [Cites] Expert Rev Anticancer Ther. 2008 Nov;8(11):1713-7 [18983231.001]
  • [Cites] Molecules. 2008;13(12):3224-35 [19104487.001]
  • [Cites] Int J Dermatol. 2008 Dec;47(12):1334-6 [19126041.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:56-8 [18067634.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S149-54 [18410801.001]
  • [Cites] N Engl J Med. 1994 May 5;330(18):1272-5 [8145782.001]
  • [Cites] Photochem Photobiol. 1993 Aug;58(2):304-12 [8415922.001]
  • [Cites] Antiviral Res. 1995 Nov;28(3):253-64 [8629817.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):885-9 [9357496.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Nov;6(11):949-56 [9367069.001]
  • [Cites] Arch Dermatol. 1997 Oct;133(10):1239-42 [9382562.001]
  • [Cites] Australas J Dermatol. 1997 Nov;38(4):187-9 [9431711.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):711-6 [9485025.001]
  • [Cites] Clin Plast Surg. 1998 Jan;25(1):1-19 [9507793.001]
  • [Cites] J Invest Dermatol. 1998 May;110(5):734-9 [9579537.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1551-70 [9620844.001]
  • [Cites] Carcinogenesis. 1998 May;19(5):723-9 [9635856.001]
  • [Cites] Development. 1998 Sep;125(18):3553-62 [9716521.001]
  • [Cites] Altern Med Rev. 1998 Dec;3(6):448-57 [9855569.001]
  • [Cites] Cell Immunol. 1999 Jan 10;191(1):10-9 [9918682.001]
  • [Cites] J Nutr. 1999 Mar;129(3):775S-778S [10082788.001]
  • [Cites] Ther Clin Risk Manag. 2008 Oct;4(5):1085-95 [19209288.001]
  • [Cites] Arch Dermatol. 2009 Feb;145(2):203-5 [19221274.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2009 Apr;18(4):276-83 [19226541.001]
  • [Cites] Am J Otolaryngol. 2009 Mar-Apr;30(2):121-33 [19239954.001]
  • [Cites] J Am Acad Dermatol. 2009 Apr;60(4):615-25 [19293009.001]
  • [Cites] Br J Dermatol. 2009 Jul;161(1):170-3 [19302071.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):127-33 [19356643.001]
  • [Cites] Photodiagnosis Photodyn Ther. 2008 Jun;5(2):134-8 [19356644.001]
  • [Cites] Photomed Laser Surg. 2009 Apr;27(2):345-9 [19382838.001]
  • [Cites] Am J Otolaryngol. 2009 May-Jun;30(3):181-92 [19410124.001]
  • [Cites] Int J Cancer. 2009 Oct 1;125(7):1678-84 [19462452.001]
  • [Cites] J Am Acad Dermatol. 2009 Jun;60(6):934-43 [19467365.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2009 Sep;23(9):1061-5 [19470041.001]
  • [Cites] BMC Cancer. 2009;9:262 [19643007.001]
  • [Cites] Facial Plast Surg Clin North Am. 2009 Aug;17(3):301-7 [19698912.001]
  • [Cites] Facial Plast Surg Clin North Am. 2009 Aug;17(3):309-24 [19698913.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1164-72 [19726763.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1202-5 [19726764.001]
  • [Cites] Dermatol Surg. 2009 Nov;35(11):1776-87 [19737291.001]
  • [Cites] Semin Cutan Med Surg. 2009 Sep;28(3):180-9 [19782942.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):171-5 [19863513.001]
  • [Cites] J Invest Dermatol. 2009 Dec;129(12):2745-6 [19901945.001]
  • [Cites] Expert Opin Pharmacother. 2009 Dec;10(18):3015-31 [19925043.001]
  • [Cites] J Cutan Med Surg. 2005 Oct;9(5):209-14 [16502198.001]
  • [Cites] Dermatol Online J. 2006;12(3):10 [16638424.001]
  • [Cites] J Fam Pract. 2006 May;55(5):suppl 1-8 [16672155.001]
  • [Cites] J Drugs Dermatol. 2006 Apr;5(4):368-9 [16673807.001]
  • [Cites] Dermatol Surg. 2006 Apr;32(4):562-8 [16681667.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1025-32 [16713457.001]
  • [Cites] J Am Acad Dermatol. 2006 Jun;54(6):1033-8 [16713458.001]
  • [Cites] J Invest Dermatol. 2006 Aug;126(8):1869-78 [16763547.001]
  • [Cites] J Am Acad Dermatol. 2006 Aug;55(2):324-7 [16844522.001]
  • [Cites] Arch Dermatol. 2006 Aug;142(8):976-82 [16924046.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Sep;4(9):717-20 [16928239.001]
  • [Cites] Dermatol Ther. 2006 Sep-Oct;19(5):306-14 [17014486.001]
  • [Cites] J Immunol. 2006 Dec 1;177(11):8123-32 [17114487.001]
  • [Cites] Nat Prod Rep. 2006 Dec;23(6):919-42 [17119640.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] Br J Dermatol. 2007 Feb;156(2):320-8 [17223873.001]
  • [Cites] Int J Dermatol. 2007 Mar;46(3):318-9 [17343595.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):427-31; discussion 431-2 [17430376.001]
  • [Cites] Br J Dermatol. 2007 May;156 Suppl 3:53-6 [17488408.001]
  • [Cites] Br J Dermatol. 2007 Jul;157(1):133-41 [17501955.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] J Drugs Dermatol. 2007 Aug;6(8):778-81 [17763606.001]
  • [Cites] Int J Dermatol. 2007 Nov;46(11):1113-7 [17988327.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 Apr;22(4):426-30 [18031503.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2007 Nov-Dec;73(6):423-5 [18032866.001]
  • [Cites] J Cutan Med Surg. 2007 Nov-Dec;11(6):195-201 [18042331.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:8-13 [18067624.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:25-31 [18067628.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:41-6 [18067631.001]
  • [Cites] Nature. 1994 Nov 3;372(6501):107-11 [7969403.001]
  • [Cites] J Am Acad Dermatol. 1994 Mar;30(3):447-51 [8113458.001]
  • [Cites] Recent Results Cancer Res. 1999;151:45-67 [10337718.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):1-8 [10389969.001]
  • [Cites] Int J Cancer. 1999 Aug 27;82(5):648-56 [10417761.001]
  • [Cites] Mol Carcinog. 1999 Aug;25(4):231-40 [10449029.001]
  • [Cites] Dermatol Surg. 1999 Jun;25(6):513-6 [10469105.001]
  • [Cites] Carcinogenesis. 1999 Oct;20(10):1939-44 [10506108.001]
  • [Cites] J Am Acad Dermatol. 1999 Dec;41(6):1002-7 [10570388.001]
  • [Cites] Br J Dermatol. 1999 Sep;141(3):415-23 [10583044.001]
  • [Cites] Cell. 2000 Jan 21;100(2):185-8 [10660040.001]
  • [Cites] Ann Clin Lab Sci. 2000 Jan;30(1):3-21 [10678579.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):479S-482S [10721933.001]
  • [Cites] Am J Clin Oncol. 2000 Apr;23(2):181-4 [10776981.001]
  • [Cites] Eur J Cancer. 2000 Jun;36(10):1292-7 [10882869.001]
  • [Cites] J Dermatolog Treat. 2008;19(5):293-9 [19160536.001]
  • [Cites] Chem Biol Interact. 2009 May 15;179(2-3):145-53 [19161993.001]
  • [Cites] Australas J Dermatol. 2009 Feb;50(1):16-22 [19178487.001]
  • [Cites] J Drugs Dermatol. 2009 Jan;8(1):35-9 [19180894.001]
  • [Cites] J Dermatolog Treat. 2003 Jun;14(2):99-106 [12775317.001]
  • [Cites] Oncogene. 2003 May 19;22(20):3152-61 [12789291.001]
  • [Cites] J Natl Cancer Inst. 2003 Aug 6;95(15):1138-49 [12902443.001]
  • [Cites] JAMA. 2003 Oct 22;290(16):2149-58 [14570950.001]
  • [Cites] Clin Exp Dermatol. 2003 Nov;28 Suppl 1:13-5 [14616805.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2004 Jan;18(1):93-5 [14678542.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):629-35 [14711141.001]
  • [Cites] J Drugs Dermatol. 2003 Dec;2(6):669-73 [14711149.001]
  • [Cites] Skin Therapy Lett. 2004 Jan;9(1):1-3 [14716439.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):33-40 [14732657.001]
  • [Cites] Arch Dermatol. 2004 Jan;140(1):41-6 [14732659.001]
  • [Cites] Lasers Surg Med. 2004;34(2):114-9 [15004822.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):127-42 [15068837.001]
  • [Cites] Cancer Res. 2004 Apr 15;64(8):2833-9 [15087400.001]
  • [Cites] Arch Dermatol. 2004 Apr;140(4):404-6 [15096367.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):714-21 [15097955.001]
  • [Cites] J Am Acad Dermatol. 2002 Sep;47(3):390-8 [12196749.001]
  • [Cites] Arch Dermatol. 2002 Sep;138(9):1165-71 [12224977.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4 Suppl):S225-8 [12271283.001]
  • [Cites] J Am Acad Dermatol. 2002 Oct;47(4):571-7 [12271303.001]
  • [Cites] Cutis. 2002 Aug;70(2 Suppl):22-9 [12353677.001]
  • [Cites] Breast Cancer Res Treat. 2002 Nov;76(1):57-64 [12408376.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):221-6 [12427541.001]
  • [Cites] Arch Dermatol. 2002 Nov;138(11):1498-502 [12437457.001]
  • [Cites] J Cutan Med Surg. 2003 Mar-Apr;7(2):101-5 [12447619.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Int J Dermatol. 2002 Nov;41(11):810-6 [12453012.001]
  • [Cites] Arch Dermatol. 2003 Jan;139(1):66-70 [12533168.001]
  • [Cites] Dermatologica. 1979;158(5):368-72 [437226.001]
  • [Cites] Hautarzt. 1978 Jun;29(6):313-8 [659114.001]
  • [Cites] Arch Dermatol. 1978 Jul;114(7):1021-2 [686718.001]
  • [Cites] Acta Derm Venereol Suppl (Stockh). 1975 Jan 27-29;74:163-6 [816129.001]
  • [Cites] Med J Aust. 1976 Jun 12;1(24):928 [979751.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Nature. 1992 Jul 2;358(6381):15-6 [1614522.001]
  • [Cites] J Am Acad Dermatol. 1992 Jul;27(1):65-9 [1619079.001]
  • [Cites] J Am Acad Dermatol. 1991 Oct;25(4):665-7 [1791225.001]
  • [Cites] J Am Acad Dermatol. 1991 May;24(5 Pt 1):731-4 [1869644.001]
  • [Cites] Nutr Cancer. 1991;15(2):97-106 [2038569.001]
  • [Cites] J Am Acad Dermatol. 1991 Mar;24(3):448-51 [2061443.001]
  • [Cites] EMBO J. 1990 Dec;9(13):4443-54 [2176152.001]
  • [Cites] J Am Acad Dermatol. 1990 Oct;23(4 Pt 1):694-700 [2229497.001]
  • [Cites] J Dermatol Surg Oncol. 1990 May;16(5):446-9 [2341658.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):759-74 [3123052.001]
  • [Cites] J Biol Chem. 1988 Aug 5;263(22):11008-14 [3134356.001]
  • [Cites] Australas J Dermatol. 1988;29(3):127-30 [3272119.001]
  • [Cites] Arch Dermatol. 1986 Jul;122(7):779-82 [3524471.001]
  • [Cites] J Am Acad Dermatol. 1986 Sep;15(3):437-43 [3760271.001]
  • [Cites] Arch Dermatol. 1985 Feb;121(2):207-13 [3977335.001]
  • [Cites] Cancer Res. 1985 Dec;45(12 Pt 1):6254-9 [4063976.001]
  • [Cites] Agents Actions. 1970 Aug;1(4):172-5 [5520364.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Oct;77(10):5754-8 [6777774.001]
  • [Cites] Dermatology. 1995;190(3):214-7 [7599384.001]
  • [Cites] J Leukoc Biol. 1995 Sep;58(3):365-72 [7665993.001]
  • [Cites] Arch Dermatol. 2009 Dec;145(12):1431-8 [20026854.001]
  • [Cites] Exp Dermatol. 2010 Feb;19(2):151-3 [20156290.001]
  • [Cites] J Am Acad Dermatol. 2003 Feb;48(2):227-32 [12582393.001]
  • [Cites] Br J Dermatol. 2003 Mar;148(3):539-43 [12653747.001]
  • [Cites] J Invest Dermatol. 2004 May;122(5):1266-76 [15140231.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):227-8 [15202841.001]
  • [Cites] Clin Dermatol. 2004 May-Jun;22(3):183-8 [15262303.001]
  • [Cites] J Am Acad Dermatol. 2004 Oct;51(4):547-55 [15389189.001]
  • [Cites] J Drugs Dermatol. 2005 Mar-Apr;4(2):221-2 [15776781.001]
  • [Cites] Arch Dermatol. 2005 Apr;141(4):467-73 [15837864.001]
  • [Cites] Dermatol Surg. 2005 Mar;31(3):371-4 [15841646.001]
  • [Cites] Br J Dermatol. 2005 May;152(5):939-47 [15888150.001]
  • [Cites] Acta Derm Venereol. 2005;85(5):424-8 [16159735.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):712-3 [16197397.001]
  • [Cites] Dermatol Clin. 2006 Jan;24(1):63-74 [16311168.001]
  • [Cites] Dermatol Clin. 2006 Jan;24(1):105-17 [16311173.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):72-8 [16403097.001]
  • [Cites] Dermatol Surg. 2006 Feb;32(2):261-7 [16442048.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):156-9 [16485883.001]
  • [Cites] J Drugs Dermatol. 2006 Feb;5(2):167-73 [16485885.001]
  • [Cites] Nutrition. 2000 Nov-Dec;16(11-12):1084-9 [11118831.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Dec;9(12):1281-6 [11142412.001]
  • [Cites] Arch Dermatol. 2001 Jan;137(1):14-6 [11176654.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):1054 [11369927.001]
  • [Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]
  • [Cites] J Invest Dermatol. 2001 Nov;117(5):1212-7 [11710935.001]
  • [Cites] Int J Dermatol. 2001 Nov;40(11):709-13 [11737438.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):149-55 [11801552.001]
  • [Cites] Nat Immunol. 2002 Feb;3(2):196-200 [11812998.001]
  • [Cites] Cell. 2002 Jan 25;108(2):153-64 [11832206.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):94-100 [11841372.001]
  • [Cites] Dermatol Surg. 2002 Feb;28(2):187 [11860435.001]
  • [Cites] J Am Acad Dermatol. 2002 Mar;46(3):470-1 [11862196.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Mar;41(3):269-85 [11880204.001]
  • [Cites] J Am Acad Dermatol. 2002 Apr;46(4):545-8 [11907505.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2067-72 [12114405.001]
  • [Cites] Clin Ther. 2002 Jun;24(6):990-1000 [12117087.001]
  • [Cites] Photochem Photobiol. 2002 Jul;76(1):73-80 [12126310.001]
  • [Cites] J Am Acad Dermatol. 2002 Aug;47(2):258-62 [12140473.001]
  • (PMID = 20725548.001).
  • [ISSN] 1941-2789
  • [Journal-full-title] The Journal of clinical and aesthetic dermatology
  • [ISO-abbreviation] J Clin Aesthet Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2921754
  •  go-up   go-down


41. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • RESULTS: The behavior of this tumor is very aggressive, resulting in poor prognosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps


42. Altan-Yaycioglu R, Bolat F, Akova YA: Basosquamous carcinoma of the lacrimal sac: a case report. Orbit; 2007 Dec;26(4):267-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma of the lacrimal sac: a case report.
  • Pathological examination revealed basal cell carcinoma of the lacrimal sac.
  • Two weeks later, the diseased sac and surrounding tissue were excised, using frozen sections to ensure adequate tumor-free margins.
  • The lacrimal sac tumor was diagnosed as basal cell carcinoma with focal squamous differentiation.
  • No tumor recurrence was detected in 1.5 years of follow-up.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097965.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


43. Eller MS, Asarch A, Gilchrest BA: Photoprotection in human skin--a multifaceted SOS response. Photochem Photobiol; 2008 Mar-Apr;84(2):339-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photoprotection in human skin--a multifaceted SOS response.
  • Human skin has developed elaborate defense mechanisms for combating a wide variety of potentially damaging environmental factors; principal among these is UV light.
  • Despite these defenses, short-term damage may include painful sunburn and long-term UV damage results in both accelerated skin aging and skin cancers such as basal cell carcinoma, squamous cell carcinoma and even malignant melanoma.
  • The following sections briefly review UV-inducible protective responses in bacteria and in skin, thymidine dinucleotides (pTT) as a powerful probe of DNA damage responses, and potential means of harnessing these inducible responses therapeutically to reduce the now enormous burden of cutaneous photodamage in our society.
  • [MeSH-major] SOS Response (Genetics). Skin / radiation effects
  • [MeSH-minor] Animals. DNA Damage. Humans. Neoplasms, Radiation-Induced / genetics. Skin Neoplasms / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18179622.001).
  • [ISSN] 0031-8655
  • [Journal-full-title] Photochemistry and photobiology
  • [ISO-abbreviation] Photochem. Photobiol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 10515
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 140
  •  go-up   go-down


44. Stelkovics E, Korom I, Marczinovits I, Molnar J, Rasky K, Raso E, Ficsor L, Molnar B, Kopper L, Krenacs T: Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy. Appl Immunohistochem Mol Morphol; 2008 Oct;16(5):433-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagen XVII/BP180 protein expression in squamous cell carcinoma of the skin detected with novel monoclonal antibodies in archived tissues using tissue microarrays and digital microscopy.
  • Collagen XVII/BP180, a hemidesmosomal adhesion protein, is lost during normal keratinocyte maturation; however, it may be reexpressed upon malignant transformation.
  • In this work, highly sensitive monoclonal antibodies 6D1 and 9G2 were produced, characterized, and used for the detection of collagen XVII in a tissue microarray series of archived samples of nonmelanocytic epithelial neoplasias, including 5 verruca vulgaris, 14 seborrheic keratosis, 38 actinic keratosis, 38 basal cell carcinoma (BCC), 15 basosquamous carcinoma, 58 squamous cell carcinoma (SCC), and 9 normal skin.
  • Digital microscopy and a new tissue microarray software linking image and patient data allowed easy and validated evaluation and quality archiving of stained samples.
  • In normal skin and benign epidermal lesions, collagen XVII protein was restricted to basal keratinocytes.
  • However, possibly as a sign of undifferentiated/transformed state, it was widely expressed in SCC showing elevated levels around invasive tumor fronts with some staining in tumor adjacent stroma, endothelium, and histiocytes.
  • Squamous component of basosquamous carcinoma showed moderate reaction, whereas islets of BCC were mainly negative reflecting the diverse genotype and phenotype, and pathogenesis of SCC and BCC.
  • These results suggest that collagen XVII neoexpression may be associated with early atypia/malignant transformation of keratinocytes.
  • Further investigations are under way to analyze the potential of these antibodies for tracing progression and metastatic potential of skin tumors.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18633319.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / Biomarkers, Tumor; 0 / Non-Fibrillar Collagens; 0 / collagen type XVII
  •  go-up   go-down


45. Ban JH, Lee JK, Jin SM, Lee KC: Basaloid squamous cell carcinoma of the external auditory canal: case report. Eur Arch Otorhinolaryngol; 2007 Jun;264(6):697-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid squamous cell carcinoma of the external auditory canal: case report.
  • Basaloid squamous cell carcinoma (BSCC) is a rare malignancy, with features of both basal cell carcinoma and squamous cell carcinoma.
  • The tumor has a predilection for the upper aerodigestive tract, and has been suggested to behave more aggressively than squamous cell carcinoma (SCC).
  • Excision of the tumor was accomplished by modified lateral temporal bone resection.
  • This report describes the first case of BSCC in this location, and includes reviews of the pathologic and clinical aspects of this disease.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Ear Canal / pathology. Ear Neoplasms / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2000 Sep;110(9):1479-82 [10983946.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 2003 Nov-Dec;65(6):332-40 [14981326.001]
  • [Cites] Arch Otolaryngol. 1980 Nov;106(11):675-9 [6252880.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1179-83 [15235344.001]
  • [Cites] Am J Otol. 2000 Jul;21(4):582-8 [10912706.001]
  • [Cites] J Otolaryngol. 2005 Jun;34(3):212-5 [16089230.001]
  • [Cites] Hum Pathol. 1986 Nov;17(11):1158-66 [3770734.001]
  • [Cites] J Plast Reconstr Aesthet Surg. 2006;59(4):424-8 [16756261.001]
  • (PMID = 17235532.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


46. Fine JD, Mellerio JE: Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol; 2009 Sep;61(3):387-402; quiz 403-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Some epidermolysis bullosa subtypes are at risk for severe injury of the bone marrow, musculoskeletal system, heart, kidney, and teeth, and for the development of squamous cell carcinoma, basal cell carcinoma, or malignant melanoma.
  • [MeSH-minor] Carcinoma, Squamous Cell / complications. Education, Medical, Continuing. Humans. Mouth Diseases / etiology. Skin Neoplasms / complications


47. Kang SY, Lee SJ, Hong SH, Chung YK, Oh HS, Kim SW, Yim DJ, Kim NK: Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin. Mol Med Rep; 2010 Sep-Oct;3(5):741-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms of 5,10-methylenetetrahydrofolate reductase and thymidylate synthase in squamous cell carcinoma and basal cell carcinoma of the skin.
  • Genetic instability resulting from mutations in repair genes, defects in folic acid metabolism or DNA synthesis has been reported to contribute significantly to the development of skin cancer.
  • Thus, the present case-control study was conducted to determine whether an association exists between the MTHFR/TS polymorphisms and squamous cell carcinoma (SCC) and/or basal cell carcinoma (BCC) among Korean individuals.
  • The study subjects comprised 95 patients with SCC, 100 patients with BCC and 207 controls with no evidence of malignancy or pre-malignant lesions.
  • Patients with skin cancer and control samples were analyzed for polymorphisms of the MTHFR or TS genes by means of polymerase chain reaction-restriction fragment length polymorphism.
  • The MTHFR 677C>T and MTHFR 1298A>C polymorphisms showed no significance with regard to the development of SCC and BCC.
  • However, within the 6 bp insertion (ins)/deletion (del) polymorphism in the 3'-untranslated region (3'-UTR) of the TS gene, the BCC group showed statistical significance with a 2.8-fold increased risk of cancer development [adjusted odds ratio (AOR)=2.821] in heterozygous mutations (0 bp/6 bp), 7.5-fold (AOR=7.539) in homozygous mutations (6 bp/6 bp) and 3-fold (AOR=3.079) upon combination of heterozygous mutations and homozygous mutations (0 bp/6 bp + 6 bp/6 bp).
  • We thus conclude that the 6 bp ins/del polymorphism in the 3'-UTR is associated with increased risk of the development of skin cancer among Korean individuals with BCC.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21472308.001).
  • [ISSN] 1791-3004
  • [Journal-full-title] Molecular medicine reports
  • [ISO-abbreviation] Mol Med Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


48. Miller KL, Karagas MR, Kraft P, Hunter DJ, Catalano PJ, Byler SH, Nelson HH: XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis; 2006 Aug;27(8):1670-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] XPA, haplotypes, and risk of basal and squamous cell carcinoma.
  • Nucleotide excision repair (NER) is instrumental in removing DNA lesions caused by ultraviolet (UV) radiation, the dominant risk factor for keratinocyte carcinoma, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • We evaluated whether BCC or SCC risk was influenced by the A23G single nucleotide polymorphism (SNP) in Xeroderma pigmentosum group A (XPA), which codes for an essential protein in NER.
  • We also investigated whether haplotypes of XPA, determined by seven haplotype-tagging SNPs, better define susceptibility to keratinocyte carcinoma.
  • Incident cases of BCC and SCC from New Hampshire were identified through dermatologists and pathology laboratories.
  • Cases of BCC (886) and of SCC (682) were compared with controls (796).
  • Using GG as the reference, the A allele was less frequent among cases of BCC (OR(AG) = 0.82, 95% CI (0.66, 1.01); OR(AA)= 0.74, 95% CI (0.53, 1.03); trend test P = 0.03) and SCC (OR(AG) = 0.85, 95% CI (0.67, 1.07); OR(AA) = 0.74, 95% CI (0.52, 1.05); trend test P = 0.05) than controls.
  • Risk from > or =3 severe sunburns was elevated for those with the GG genotype only, and this interaction was nearly significant for BCC (P = 0.07).
  • Using a haplotype analysis identifying seven common XPA haplotypes indicated that the A23G polymorphism alone captured the differences in susceptibility to keratinocyte carcinoma.
  • The common G allele of the A23G polymorphism was associated with an increased risk of BCC and SCC and this polymorphism appeared to be the determining polymorphism in XPA that alters cancer susceptibility.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Carcinoma, Squamous Cell / genetics. Haplotypes / genetics. Skin Neoplasms / genetics. Xeroderma Pigmentosum Group A Protein / genetics

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16513681.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA006515; United States / NCI NIH HHS / CA / R01 CA082354; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein
  •  go-up   go-down


49. Kunte C, Konz B: [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin]. Hautarzt; 2007 May;58(5):419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current recommendations in the treatment of basal cell carcinoma and squamous cell carcinoma of the skin].
  • [Transliterated title] Aktuelle Therapieempfehlungen für das Basalzellkarzinom und Plattenepithelkarzinom der Haut.
  • The incidence of the most common tumors of the skin, basal cell carcinoma and squamous cell carcinoma, has risen rapidly in recent years.
  • They must be able to develop therapeutic strategies adapted to the tumor and the patient.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm, Residual / pathology. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Prognosis. Radiotherapy, Adjuvant. Skin / pathology. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Strahlenther Onkol. 2001 May;177(5):240-6 [11398609.001]
  • [Cites] Facial Plast Surg. 1997 Apr;13(2):79-82 [9243982.001]
  • [Cites] Hautarzt. 2005 May;56(5):430-40 [15815888.001]
  • [Cites] J Am Acad Dermatol. 2004 May;50(5):722-33 [15097956.001]
  • [Cites] J Dermatol Surg Oncol. 1994 May;20(5):350 [8176049.001]
  • [Cites] Recent Results Cancer Res. 2002;160:219-24 [12079216.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):915-9 [9041153.001]
  • [Cites] BMJ. 2004 Sep 25;329(7468):705 [15364703.001]
  • [Cites] Dermatol Surg. 2000 Aug;26(8):759-64 [10940063.001]
  • [Cites] Br J Dermatol. 2000 Apr;142(4):752-7 [10792227.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Acta Derm Venereol. 2004;84(3):218-22 [15202839.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):91-5 [17190625.001]
  • [Cites] Br J Dermatol. 2006 Jun;154(6):1202-3 [16704658.001]
  • [Cites] Lancet. 1988 Apr 9;1(8589):795-7 [2895318.001]
  • [Cites] Dermatol Surg. 2006 Nov;32(11):1309-21 [17083582.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Sep;20(8):926-30 [16922939.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Mar;4(3):260-2 [16626324.001]
  • [Cites] J Dermatol Surg Oncol. 1991 Jul;17(7):574-8 [1860987.001]
  • [Cites] Br J Cancer. 1997;76(1):100-6 [9218740.001]
  • [Cites] Arch Dermatol. 2004 Oct;140(10 ):1286-7 [15492202.001]
  • [Cites] Hautarzt. 1975 Dec;26(12):647-50 [1213885.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):642-50 [15061849.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 May;4(5):441-3 [16686614.001]
  • [Cites] Hautarzt. 1995 Sep;46(9):607-14 [7591764.001]
  • [Cites] J Am Acad Dermatol. 2007 Jan;56(1):125-43 [17190630.001]
  • [Cites] J Am Acad Dermatol. 2003 Sep;49(3):483-6 [12963913.001]
  • [Cites] Eur J Dermatol. 2002 Nov-Dec;12 (6):569-72 [12459530.001]
  • [Cites] Br J Dermatol. 2002 Dec;147(6):1227-36 [12452875.001]
  • [Cites] Recent Results Cancer Res. 2002;160:240-5 [12079219.001]
  • (PMID = 17443305.001).
  • [ISSN] 0017-8470
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 31
  •  go-up   go-down


50. Harrison SC, Bergfeld WF: Ultraviolet light and skin cancer in athletes. Sports Health; 2009 Jul;1(4):335-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ultraviolet light and skin cancer in athletes.
  • The incidence of melanoma and nonmelanoma skin cancers is increasing worldwide.
  • Ultraviolet light exposure is the most important risk factor for cutaneous melanoma and nonmelanoma skin cancers.
  • Nonmelanoma skin cancer includes basal cell carcinoma and squamous cell carcinoma.
  • Constitutive skin color and genetic factors, as well as immunological factors, play a role in the development of skin cancer.
  • Ultraviolet light also causes sunburn and photoaging damage to the skin.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):1012-3 [8959974.001]
  • [Cites] J Am Acad Dermatol. 2008 Aug;59(2):316-23 [18485529.001]
  • [Cites] J Am Acad Dermatol. 1999 Jan;40(1):114-6 [9922027.001]
  • [Cites] J Cosmet Dermatol. 2006 Mar;5(1):39-47 [17173570.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2832-8 [17179460.001]
  • [Cites] J Am Acad Dermatol. 2008 May;58(5 Suppl 2):S129-32 [18410798.001]
  • [Cites] Acta Clin Croat. 2008 Mar;47(1):25-30 [18714644.001]
  • [Cites] Dermatology. 2000;201(1):44-5 [10971059.001]
  • [Cites] Br J Dermatol. 2001 Mar;144(3):471-5 [11260001.001]
  • [Cites] Med Sci Sports Exerc. 2001 Aug;33(8):1385-6 [11474342.001]
  • [Cites] Sports Med. 2002;32(5):309-21 [11929358.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):367-75 [12637916.001]
  • [Cites] J Am Acad Dermatol. 2005 Aug;53(2):237-41 [16021116.001]
  • [Cites] Arch Dermatol. 2005 Aug;141(8):1032-4 [16103334.001]
  • [Cites] J Cutan Pathol. 2006 Mar;33(3):191-206 [16466506.001]
  • [Cites] J Cutan Pathol. 2006 Apr;33(4):261-79 [16630176.001]
  • [Cites] J Am Acad Dermatol. 2006 Jul;55(1):1-19 [16781287.001]
  • [Cites] Arch Dermatol. 2006 Nov;142(11):1471-4 [17116838.001]
  • [Cites] Int J Cancer. 2007 Mar 1;120(5):1116-22 [17131335.001]
  • [Cites] Am J Prev Med. 2007 Mar;32(3):210-6 [17296473.001]
  • [Cites] FDA Consum. 2006 Sep-Oct;40(5):4 [17326301.001]
  • [Cites] Nat Clin Pract Oncol. 2007 Aug;4(8):462-9 [17657251.001]
  • [Cites] Br J Dermatol. 2007 Dec;157 Suppl 2:47-51 [18067632.001]
  • [Cites] Clin Dermatol. 2008 Jan-Feb;26(1):12-5 [18280899.001]
  • [Cites] Adv Exp Med Biol. 2008;624:89-103 [18348450.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2008 May;22(5):606-15 [18410618.001]
  • [Cites] Int J Sport Nutr Exerc Metab. 2008 Apr;18(2):204-24 [18458363.001]
  • [Cites] South Med J. 1997 Jan;90(1):55-8 [9003825.001]
  • (PMID = 23015891.001).
  • [ISSN] 1941-7381
  • [Journal-full-title] Sports health
  • [ISO-abbreviation] Sports Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3445124
  • [Keywords] NOTNLM ; athletes / melanoma / skin cancer / ultraviolet light
  •  go-up   go-down


51. Moscarelli L, Zanazzi M, Mancini G, Rossi E, Caroti L, Rosso G, Bertoni E, Salvadori M: Keratinocyte cancer prevention with ACE inhibitors, angiotensin receptor blockers or their combination in renal transplant recipients. Clin Nephrol; 2010 Jun;73(6):439-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Skin cancer (SC) is the most frequent malignancy after renal transplantation (RT), especially squamous and basal cell carcinoma.
  • The observation that angiotensin II is a potent angiogenic and growth factor raises the possibility that blocking its effects could reduce the incidence of skin cancer.
  • OBJECTIVES: To evaluate the incidence of keratinocyte cancer in RT recipients, the timing of occurrence of the skin events after RT; to compare the incidence of SC in our RT recipients and in RT patients on angiotensin converting enzyme inhibitors (ACEi), angiotensin receptor blockers therapy (ARBs) and their combination.
  • BCC was the most frequent type of keratinocyte cancer in non users and in users.
  • No association with incidence of BCC or SCC was observed for other classes of antihypertensive drugs (calcium antagonists, beta-blockers, alpha-blockers).
  • [MeSH-major] Angiotensin Receptor Antagonists. Angiotensin-Converting Enzyme Inhibitors / administration & dosage. Kidney Transplantation. Receptors, Angiotensin / therapeutic use. Skin Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Female. Humans. Male. Middle Aged. Postoperative Complications. Risk Factors


52. Mitsuhashi T, Itoh T, Shimizu Y, Ban S, Ogawa F, Hirose T, Shimizu M: Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants. J Cutan Pathol; 2006 Mar;33(3):246-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma of the skin: dual differentiations to rare basosquamous and spindle cell variants.
  • Basosquamous carcinoma (BSC) is defined as a tumor containing the areas of both basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) with a transition zone linking the two.
  • Spindle cell squamous carcinoma (SCSC) may have a variable component of conventional SCC and spindle cells.
  • Grossly, the lesion measured 8.5 x 6.0 x 1.8 cm and consisted of a gray-white and focally black tumor.
  • Microscopically, a non-ulcerated upper part of the tumor consisted of large polygonal squamoid cells with occasional keratinization (SCC), trabecular growth of basaloid cells with peripheral palisading (BCC), and an area in which both the components were intermingled.
  • The rest of the tumor was a myxoid area with elongated fusiform spindle cells, which appeared to arise from conventional SCC.
  • Immunohistochemically, the tumor cells in the SCSC (both conventional and spindle cell) area co-expressed CAM5.2, and vimentin.
  • Ber-EP4 was positive in the BCC area with the transition zone of SCC and BCC showing diminished staining.
  • To our knowledge, this is the first case report of SCC of the skin that has dual differentiations to BSC and SCSC.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / analysis. Cell Transformation, Neoplastic. Female. Humans. Immunohistochemistry. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16466514.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


53. Weinstock MA: Controversies in the public health approach to keratinocyte carcinomas. Br J Dermatol; 2006 May;154 Suppl 1:3-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Controversies in the public health approach to keratinocyte carcinomas.
  • Keratinocyte carcinomas are very common cancers in fair-skinned populations throughout the world.
  • The term 'keratinocyte carcinoma' includes basal and squamous cell carcinoma of the skin, but not other cancers that may be included under the more ambiguous term 'nonmelanoma skin cancer'.
  • Mortality from keratinocyte carcinoma reveals distinct patterns suggestive of an important role of human papilloma virus infection.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16712708.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 1406-16-2 / Vitamin D
  • [Number-of-references] 12
  •  go-up   go-down


54. Krüger-Corcoran D, Stockfleth E, Jürgensen JS, Maltusch A, Nindl I, Sterry W, Lange-Asschenfeldt B, Ulrich C: [Human papillomavirus-associated warts in organ transplant recipients. Incidence, risk factors, management]. Hautarzt; 2010 Mar;61(3):220-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Human papillomaviruses infect the squamous epithelia of the skin and cause warts, and are occasionally found in squamous cell carcinomas.
  • Since cell-mediated immunity plays a crucial role in the control of HPV-infections, organ transplant recipients, unable to mount an adequate T-helper 1 cell-mediated immune surveillance, frequently develop widespread and resistant induced warts.
  • Skin tumors, especially squamous cell carcinomas, are the most common post-transplantation neoplasm.
  • Warts, actinic keratoses and invasive squamous cell carcinomas are known to develop at the same time in the areas.
  • The role of HPV in the development of invasive squamous cell carcinoma under immunosuppression, remains to be elucidated in respect to common risk factors and increased numbers of warts potentially identifying patients at increased risk for carcinoma.
  • We prospectively studied 1690 organ transplant recipients in the dermatology clinic at the Charité University Hospital in Berlin, to evaluate risk factors being involved in the development of HPV-induced warts and to assess a potential association of with the development of non-melanoma skin cancers in this population.
  • The presence of more than 10 verrucae was associated with the development of actinic keratoses, invasive squamous cell carcinoma and basal cell carcinoma.
  • This study shows clear evidence that certain risk factors of skin carcinogenesis in organ transplant recipient such as increased age at transplantation, a high dose of immunosuppression related to a specific type of graft and use of azathioprine or cyclosporine are strongly associated with an increased incidence of warts.
  • Furthermore, HPV-induced verrucae vulgares could be used as a potential predictor for the development of coincidental non melanoma skin cancer in organ transplant recipients and therefore could serve as an early identification marker of skin cancer high-risk patients.
  • [MeSH-major] Carcinoma, Squamous Cell / epidemiology. Organ Transplantation / statistics & numerical data. Papillomaviridae. Postoperative Complications / epidemiology. Skin Neoplasms / epidemiology. Warts / epidemiology

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Warts.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Liver Transpl. 2006 Dec;12(12):1883-7 [17133572.001]
  • [Cites] N Z Med J. 1995 Jun 28;108(1002):255-6 [7617333.001]
  • [Cites] Br J Dermatol. 1993 Mar;128(3):264-70 [8385983.001]
  • [Cites] Ann Dermatol Venereol. 2002 Mar;129(3):291-3 [11988683.001]
  • [Cites] Cancer Res. 1963 Sep;23:1226-43 [14070379.001]
  • [Cites] Recent Results Cancer Res. 2002;160:251-8 [12079221.001]
  • [Cites] Br J Dermatol. 2005 Jan;152(1):122-9 [15656812.001]
  • [Cites] J Invest Dermatol. 2007 Jul;127(7):1647-56 [17380113.001]
  • [Cites] Transpl Int. 2007 Mar;20(3):238-46 [17291217.001]
  • [Cites] Br J Dermatol. 2010 Jan;162(1):176-84 [19709100.001]
  • [Cites] Transplantation. 2000 Jan 15;69(1):44-9 [10653378.001]
  • [Cites] Acta Derm Venereol. 1991;71(1):63-6 [1711753.001]
  • [Cites] Am J Transplant. 2005 Feb;5(2):406-11 [15644002.001]
  • [Cites] Histopathology. 1989 Feb;14(2):129-39 [2540085.001]
  • [Cites] J R Soc Med. 1995 Feb;88(2):61-2 [7769594.001]
  • [Cites] Int Immunopharmacol. 2005 Jan;5(1):107-15 [15589468.001]
  • [Cites] Lancet. 1989 Jan 21;1(8630):124-9 [2563048.001]
  • [Cites] Clin Exp Dermatol. 2005 Nov;30(6):717-8 [16197401.001]
  • [Cites] Br J Dermatol. 2003 Nov;149 Suppl 66:20-4 [14616341.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1079-85 [15381547.001]
  • [Cites] Dermatol Ther. 2005 Jan-Feb;18(1):19-27 [15842609.001]
  • [Cites] J Am Acad Dermatol. 1997 Sep;37(3 Pt 1):445-9 [9308561.001]
  • [Cites] Dermatology. 2003;206(2):148-52 [12592083.001]
  • [Cites] Eur J Dermatol. 2007 Mar-Apr;17(2):140-5 [17337398.001]
  • [Cites] J Invest Dermatol. 2005 Jul;125(1):98-107 [15982309.001]
  • [Cites] Nephrol Dial Transplant. 1994;9(4):416-20 [8084456.001]
  • [Cites] Arch Dermatol. 2002 Jan;138(1):61-5 [11790168.001]
  • [Cites] Br J Dermatol. 2007 Apr;156(4):687-92 [17326748.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2695-700 [12750299.001]
  • [Cites] Ger Med Sci. 2004 Oct 29;2:Doc08 [19675691.001]
  • [Cites] Am J Kidney Dis. 2000 Jul;36(1):167-76 [10873887.001]
  • [Cites] Lasers Surg Med. 2002;30(2):135-40 [11870793.001]
  • [Cites] Laryngoscope. 2004 Jul;114(7):1151-6 [15235339.001]
  • [Cites] Dermatol Surg. 2004 Apr;30(4 Pt 2):604-9 [15061843.001]
  • [Cites] Nature. 1957 Mar 30;179(4561):663-6 [13418758.001]
  • [Cites] Acta Derm Venereol. 2006;86(1):25-8 [16585985.001]
  • [Cites] Nephron. 1997;77(4):422-6 [9434064.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2006 Oct;22(5):265-6 [16948830.001]
  • [Cites] Hautarzt. 2002 Aug;53(8):524-33 [12221466.001]
  • (PMID = 20165825.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


55. Maeda D, Fujii A, Yamaguchi K, Tominaga T, Fukayama M, Mori M: Sarcomatoid carcinoma with a predominant basaloid squamous carcinoma component: the first report of an unusual biphasic tumor of the ureter. Jpn J Clin Oncol; 2007 Nov;37(11):878-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid carcinoma with a predominant basaloid squamous carcinoma component: the first report of an unusual biphasic tumor of the ureter.
  • Malignant tumors of the ureter that display biphasic patterns are very rare; they include carcinosarcomas, sarcomatoid carcinomas and carcinomas with pseudosarcomatous stroma.
  • Although the distinction between carcinosarcomas and sarcomatoid carcinomas has been extensively discussed in the past, the recent World Health Organization classification of urinary tract tumors (2004) does not distinguish the two lesions and use the term sarcomatoid carcinoma to represent these biphasic tumors.
  • The epithelial components of previously reported ureteral biphasic tumors comprise transitional cell carcinoma, squamous cell carcinoma, carcinoma in situ, small cell carcinoma and adenocarcinoma.
  • In this paper, we report the first case of sarcomatoid carcinoma of the ureter with a predominant basaloid squamous carcinoma component.
  • A 63-year-old man who had developed asymptomatic gross hematuria was diagnosed with a right ureteral tumor and underwent a right nephroureterectomy.
  • Macroscopic examination of the excised tumor revealed a polypoid mass.
  • Histopathologic examination exposed a tumor with malignant epithelial and sarcomatous components.
  • The malignant epithelial component was predominantly composed of basaloid squamous carcinoma, and the sarcomatous component was mostly composed of undifferentiated spindle cells.
  • A small focus of a chondrosarcomatous component was present.
  • We believe that the findings of this case study will increase the morphological diversity used for diagnosing malignant tumors of the ureter.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Mixed Tumor, Malignant / pathology. Sarcoma / pathology. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18057014.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Ball EA, Hussain M, Moss AL: Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol; 2005 May;30(3):259-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.
  • The development of a basal cell carcinoma within a naevus sebaceous of Jadassohn (NSJ) has commonly been reported.
  • However, the development of a squamous cell carcinoma (SCC) is rare.
  • Of these only one was a case of simultaneous occurrence of squamous and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Multiple Primary / etiology. Nevus / complications. Sebaceous Gland Neoplasms / complications
  • [MeSH-minor] Adult. Humans. Male. Skin Neoplasms / etiology. Skin Neoplasms / pathology


57. Filip A, Clichici S, Daicoviciu D, Adriana M, Postescu ID, Perde-Schrepler M, Olteanu D: Photochemoprevention of cutaneous neoplasia through natural products. Exp Oncol; 2009 Mar;31(1):9-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human tumors, representing 30% of the new cases of malignancies diagnosed each year.
  • Ultraviolet radiation (UV) from the sun is a major cause of non-melanoma skin cancer in humans.
  • Here we review the progress in the research of new and existing agents developed to protect the skin exposed to UV.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Cat's Claw. Flavonoids / therapeutic use. Phenols / therapeutic use. Phytotherapy. Polypodium. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19300410.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents; 0 / Flavonoids; 0 / Phenols; 0 / Plant Preparations; 0 / Polyphenols; 0 / Silymarin; 4RKY41TBTF / silybin
  • [Number-of-references] 62
  •  go-up   go-down


58. Steele CL, Shea CR, Petronic-Rosic V: Epidermolytic hyperkeratosis within infundibular cysts. J Cutan Pathol; 2007 Apr;34(4):360-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EH has been observed as an incidental finding in tissue adjacent to and within lesions such as nevi, scars, malignant melanoma, squamous cell carcinoma, basal cell carcinoma, and seborrheic keratoses.
  • We present two cases of EH within infundibular type follicular cysts, a rare finding only once otherwise reported in 1978.
  • [MeSH-minor] Aged. Carcinoma, Basal Cell / complications. Carcinoma, Squamous Cell / complications. Female. Humans. Incidental Findings. Male. Skin Neoplasms / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17381810.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


59. Sikora AG, Morris LG, Sturgis EM: Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg; 2009 Apr;135(4):402-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men.
  • OBJECTIVE: To test the hypothesis of a bidirectional association of anogenital and oral cavity/pharyngeal human papillomavirus (HPV)-associated cancers in men.
  • The risk of second primary HPV-associated cancers did not vary significantly by age, race, year of diagnosis, or geographic location but was greater among never-married men, particularly for anal cancer following oral cavity/pharyngeal cancer (SIR, 6.5; 95% CI,1.8-16.7 in never-married men, but SIR, 1.6; 95% CI, 0.7-3.1 in ever-married men) and for tonsillar cancer following anogenital cancer (SIR, 13.0; 95% CI, 3.5-33.2 in never-married men, but SIR, 3.8; 95% CI, 1.0-9.7 in ever-married men).
  • [MeSH-minor] Adult. Carcinoma, Basosquamous / epidemiology. Carcinoma, Basosquamous / virology. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / virology. Humans. Incidence. Male. Marital Status. Papillomavirus Infections / epidemiology. SEER Program

  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19380365.001).
  • [ISSN] 1538-361X
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Staiano JJ, Wong L, Butler J, Searle AE, Barton DP, Harris PA: Flap reconstruction following gynaecological tumour resection for advanced and recurrent disease--a 12 year experience. J Plast Reconstr Aesthet Surg; 2009 Mar;62(3):346-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flap reconstruction following gynaecological tumour resection for advanced and recurrent disease--a 12 year experience.
  • We have reviewed all the cases of flap reconstruction following resection of a gynaecological malignancy at the Royal Marsden Hospital over 12 years from 1993 until 2005.
  • Squamous cell carcinoma was the most common histological type, accounting for 71% of cases, with adenocarcinoma, Paget disease, leiomyosarcoma, melanoma and basosquamous carcinoma making up the remainder.
  • Most patients (73%) had recurrent disease at the time of reconstruction and most patients (80%) had been treated with radiotherapy either before and/or after surgery.
  • This group of patients often have advanced disease and a limited life span.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / methods. Surgical Flaps / blood supply
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Surgical Wound Infection / prevention & control. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18784004.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


61. Padgett JK: Cutaneous lesions: benign and malignant. Facial Plast Surg Clin North Am; 2005 May;13(2):195-202, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lesions: benign and malignant.
  • This article reviews the clinical characteristics, histology, biologic behavior, and recommended treatment for several benign and malignant lesions that may arise on the head and neck.
  • Basal and squamous cell carcinoma, lentigo maligna and lentigo maligna melanoma, dermatofibrosarcoma protuberans, and Merkel cell carcinoma are malignant lesions for which surgical excision is the recommended treatment.
  • Local flap reconstruction may be used to address the surgical defects resulting from excision of these benign and malignant conditions.
  • [MeSH-major] Head and Neck Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / surgery. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / surgery. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Dermatofibrosarcoma / diagnosis. Dermatofibrosarcoma / surgery. Humans. Hutchinson's Melanotic Freckle / diagnosis. Hutchinson's Melanotic Freckle / surgery. Nevus, Pigmented / diagnosis. Nevus, Pigmented / surgery. Risk Factors. Scalp. Sunlight / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15817400.001).
  • [ISSN] 1064-7406
  • [Journal-full-title] Facial plastic surgery clinics of North America
  • [ISO-abbreviation] Facial Plast Surg Clin North Am
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


62. Leverkus M, Finner AM, Pokrywka A, Franke I, Gollnick H: Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans. Dermatology; 2008;217(3):215-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic squamous cell carcinoma of the ankle in long-standing untreated acrodermatitis chronica atrophicans.
  • Occasionally, B-cell lymphoma may develop in these patients, and additional neoplastic complications such as basal cell carcinoma or squamous cell carcinoma (SCC) have been reported once each over the past 60 years.
  • [MeSH-major] Acrodermatitis / complications. Borrelia burgdorferi. Carcinoma, Squamous Cell / etiology. Lyme Disease / complications. Skin Neoplasms / etiology
  • [MeSH-minor] Aged, 80 and over. Ankle. Chronic Disease. Female. Humans. Neoplasm Metastasis


63. Anderegg U, Breitschwerdt K, Köhler MJ, Sticherling M, Haustein UF, Simon JC, Saalbach A: MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines. Exp Dermatol; 2005 Sep;14(9):709-18
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MEL4B3, a novel mRNA is induced in skin tumors and regulated by TGF-beta and pro-inflammatory cytokines.
  • Tumor-stroma interactions play a decisive role in the growth and metastasis of solid tumors, and involve signalling either by soluble mediators or direct cell-cell interaction.
  • Here, we report the isolation and characterisation of a novel cDNA (MEL4B3), which is induced in cultured dermal fibroblasts exposed to supernatants of melanoma cell lines.
  • In situ hybridisation revealed the expression of MEL4B3 in malignant melanoma increasing with tumor depth; in basal cell carcinoma and in squamous cell carcinoma.
  • MEL4B3 was barely detectable in normal skin or non-malignant melanocytic naevi.
  • Furthermore, MEL4B3 was expressed at high level in the epidermis of psoriatic skin.
  • In vitro, the expression of MEL4B3 was found to be induced by the exposure of human dermal fibroblasts to melanoma cell culture supernatants or to transforming growth factor-beta, interleukin-1 and tumor necrosis factor-alpha.
  • The expression MEL4B3 therefore reflects closely cell activation occurring during tumor growth, metastasis and inflammation.
  • [MeSH-major] Neoplasm Proteins / biosynthesis. RNA, Messenger / metabolism. Skin Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Amino Acid Sequence. Base Sequence. Blotting, Northern. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Cells, Cultured. Culture Media / metabolism. Culture Media / pharmacology. Culture Media, Conditioned / pharmacology. Cytokines / metabolism. DNA, Complementary / metabolism. Fibroblasts / metabolism. Flow Cytometry. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Inflammation. Keratinocytes / metabolism. Microcirculation. Molecular Sequence Data. Neoplasm Metastasis. Polymerase Chain Reaction. RNA, Complementary / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098131.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Culture Media; 0 / Culture Media, Conditioned; 0 / Cytokines; 0 / DNA, Complementary; 0 / FNDC1 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Complementary; 0 / RNA, Messenger; 0 / Transforming Growth Factor beta
  •  go-up   go-down


64. Asadi-Amoli F, Khoshnevis F, Haeri H, Jahanzad I, Pazira R, Shahsiah R: Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma. Am J Clin Pathol; 2010 Jul;134(1):22-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative examination of androgen receptor reactivity for differential diagnosis of sebaceous carcinoma from squamous cell and basal cell carcinoma.
  • Sebaceous carcinoma (SEB) is the most important malignant tumor of the eyelid.
  • Early diagnosis and proper treatment significantly improve the outcome.
  • SEB should be differentiated histopathologically from basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).
  • In this study, the expression of androgen receptor (AR) in SEB, SCC, and BCC was evaluated.
  • Along with other markers and morphologic features, AR can be helpful in the diagnosis of SEB and its differentiation from SCC and BCC.
  • [MeSH-major] Adenocarcinoma, Sebaceous / diagnosis. Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Eyelid Neoplasms / diagnosis. Receptors, Androgen / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20551262.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Androgen
  •  go-up   go-down


65. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • Among SCC in all samples, tumor tissue lack to express Bcl-2 positivity.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In three histological variants of SK expresseion of Bcl-2 protein was in areas of basaloid proliferation, while in areas of squamous differentiation was negative.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • In SCC, lack of Bcl-2 expression indicates that origin of tumor cells is from more differentiated suprabasal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism


66. Rigel DS: Cutaneous ultraviolet exposure and its relationship to the development of skin cancer. J Am Acad Dermatol; 2008 May;58(5 Suppl 2):S129-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous ultraviolet exposure and its relationship to the development of skin cancer.
  • Skin cancer is becoming an increasingly important public health problem.
  • Multiple studies have now demonstrated a relationship between ultraviolet exposure and increased risk of developing skin cancer.
  • However, the specifics of that association are somewhat different for malignant melanoma, basal cell carcinoma, and squamous cell carcinoma.
  • [MeSH-major] Skin / radiation effects. Skin Neoplasms / etiology. Sunlight / adverse effects. Ultraviolet Rays / adverse effects
  • [MeSH-minor] Australia / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / prevention & control. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / prevention & control. Humans. Melanoma / epidemiology. Melanoma / etiology. Melanoma / prevention & control. Risk Assessment. Time Factors. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18410798.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 43
  •  go-up   go-down


67. Askari SK, Schram SE, Wenner RA, Bowers S, Liu A, Bangerter AK, Warshaw EM: Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population. J Am Acad Dermatol; 2007 May;56(5):739-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prospectively collected presenting signs/symptoms of biopsy-proven melanoma, basal cell carcinoma, squamous cell carcinoma, and seborrheic keratosis in an elderly male population.
  • BACKGROUND: Presenting signs/symptoms of skin cancer may aid in earlier detection and diagnosis.
  • OBJECTIVE: We sought to compare prospectively collected, presenting signs/symptoms of malignant melanoma (MM), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and seborrheic keratosis (SK).
  • METHODS: This analysis was part of a larger study on teledermatology involving 3039 skin neoplasms in 2152 patients at a Department of Veterans Affairs medical center.
  • At presentation, participants were asked about signs/symptoms of specific skin lesions.
  • In all, 912 biopsy-proven MM (39), BCC (411), SCC (238), and SK (224) were included in this analysis.
  • RESULTS: "No symptoms" was reported more often with MM (82%) as compared with BCC (relative risk [RR] 2.26, confidence interval [CI] 1.86, 2.75), SCC (RR 3.31, CI 2.54, 4.32), or SK (RR 2.0, CI 1.61, 2.48; all P < .0001).
  • Tenderness was more commonly reported with SCC (40%) as compared with MM (RR 15.9, CI 2.28, 110.69), SK (RR 3.0, CI 2.11, 4.39), or BCC (RR 2.6, CI 1.97, 3.38; all P < .0001).
  • Bleeding was more commonly reported with BCC (37%) as compared with SK (RR 2.3, CI 1.67, 3.20), SCC (RR 1.6, CI 1.22, 2.05), or MM (RR 29.8, CI 1.89, 469.65; all P <or= .007).
  • CONCLUSION: This study describes common signs/symptoms of BCC, SCC, and SK.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Squamous Cell / diagnosis. Keratosis, Seborrheic / diagnosis. Melanoma / diagnosis. Skin Diseases / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Humans. Male. Middle Aged. Prospective Studies. Skin Neoplasms / diagnosis


68. Jones M Pd Fiaca Faca: Dermatological effects from years in the sun: compounding opportunities. Int J Pharm Compd; 2006 Sep-Oct;10(5):336-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Overexposure to the ultraviolet rays of the sun and tanning beds is a major cause of skin damage and the main cause of precancerous and cancerous skin lesions.
  • Unless detected and treated, actinic keratosis can progress to skin cancer.
  • The three main types of skin cancer are basal cell carcinoma, squamous cell carcinoma, and melanoma.
  • A number of treatment options are available for skin cancers, including topical preparations, systemic chemotherapy, photodynamic therapy, and surgery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23974311.001).
  • [ISSN] 1092-4221
  • [Journal-full-title] International journal of pharmaceutical compounding
  • [ISO-abbreviation] Int J Pharm Compd
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Leibovitch I, Huilgol SC, Selva D, Richards S, Paver R: Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery. J Am Acad Dermatol; 2005 Jun;52(6):997-1002
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous squamous carcinoma in situ (Bowen's disease): treatment with Mohs micrographic surgery.
  • BACKGROUND: Bowen's disease (BD), also known as squamous intraepidermal carcinoma, is a malignant skin tumor with a potential to progress to invasive carcinoma.
  • METHODS: This prospective, multicenter, case series included all patients in Australia treated with MMS for BD, who were monitored by the Skin and Cancer Foundation between 1993 and 2002.
  • In 50.7% of cases it was a recurrent tumor.
  • In 20% the tumor was initially misdiagnosed as basal cell carcinoma or squamous cell carcinoma.
  • [MeSH-major] Bowen's Disease / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Bowen's Disease.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15928618.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


70. Yu L, Galan A, McNiff JM: Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma. J Cutan Pathol; 2009 Oct;36(10):1074-176
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveats in BerEP4 staining to differentiate basal and squamous cell carcinoma.
  • BACKGROUND: Superficial skin biopsies of basal cell carcinoma (BCC) represent some of the most common dermatopathology specimens.
  • Superficial shave biopsies containing partial samples of lesions with squamatization present difficulties in distinguishing BCC from squamous cell carcinoma (SCC).
  • METHODS: We collected 12 cases of superficial biopsies of BCC with centrally located cords and strands suggesting squamous differentiation at the Yale Dermatopathology Laboratory over a 3-month period and stained them with BerEP4.
  • CONCLUSIONS: BerEP4 labeling is not reliable in superficial biopsies of BCC with squamoid features.
  • It is important to be aware of this caveat in interpreting BerEP4 staining for BCC and SCC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Staining and Labeling


71. Tatiana K S C, Somers GR, Pope E, Zuker RM: Predisposing factors and outcomes of malignant skin tumors in children. Plast Reconstr Surg; 2010 Aug;126(2):508-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predisposing factors and outcomes of malignant skin tumors in children.
  • BACKGROUND: Although benign and metastatic tumors occur in children, primary malignant skin tumors are uncommon in the pediatric population.
  • In this study, the authors aimed to determine the incidence, risk factors, treatment, reconstruction details, and outcome of malignant skin tumors occurring in pediatric patients at the Hospital for Sick Children.
  • METHODS: The electronic database (CoPath) of the pathology department was searched for all cases of malignant skin tumors treated surgically between January of 2000 and September of 2008.
  • RESULTS: Eighteen patients had been diagnosed and treated surgically for malignant skin tumors.
  • Diagnosis of malignant melanoma was made in 14 patients, diagnosis of basal cell carcinoma was made in four patients, and diagnosis of squamous cell carcinoma was made in one patient.
  • Gorlin syndrome was an underlying predisposing condition in three patients with basal cell carcinoma.
  • All cases of basal cell carcinoma and squamous cell carcinoma underwent surgical resection and primary closure or skin graft.
  • Of the patients with malignant melanoma, seven underwent surgical excision and primary closure and five had excision and skin graft.
  • CONCLUSIONS: Malignant skin tumors are rare in children.
  • In accordance with previously published data, malignant melanoma was the most frequent tumor in our study.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Sentinel Lymph Node Biopsy / methods. Skin Neoplasms / epidemiology. Skin Neoplasms / surgery. Skin Transplantation / methods
  • [MeSH-minor] Adolescent. Age Distribution. Canada / epidemiology. Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Causality. Child. Child, Preschool. Cohort Studies. Databases, Factual. Dermatology / methods. Female. Follow-Up Studies. Humans. Immunohistochemistry. Incidence. Male. Melanoma / epidemiology. Melanoma / pathology. Melanoma / surgery. Neoplasm Staging. Sex Distribution. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375763.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Jarrett P, Salmon P: Carcinomas in the Bay of Plenty: incomplete excision rates. N Z Med J; 2006;119(1228):U1811
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinomas in the Bay of Plenty: incomplete excision rates.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Carcinoma, Basosquamous / surgery. Dermatology / statistics & numerical data. Humans. New Zealand. Treatment Failure

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] N Z Med J. 2004 Apr 23;117(1192):U848 [15107870.001]
  • (PMID = 16462921.001).
  • [ISSN] 1175-8716
  • [Journal-full-title] The New Zealand medical journal
  • [ISO-abbreviation] N. Z. Med. J.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] New Zealand
  •  go-up   go-down


73. Yenidunya MO, Demirseren ME, Ceran C: Bilobed flap reconstruction in infraorbital skin defects. Plast Reconstr Surg; 2007 Jan;119(1):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilobed flap reconstruction in infraorbital skin defects.
  • Improper closure of skin defects involving this region may lead to deformity in the lower lid and to ectropion.
  • This report presents the authors' experience with 15 patients who had infraorbital skin defects reconstructed with the bilobed flap from the zygomatic and lateral cheek regions.
  • Pathologic diagnoses included basal cell carcinoma, squamous cell carcinoma, melanoma, and hemangioma.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255668.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Nilsson K, Landberg G: Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells. Int J Cancer; 2006 Mar 1;118(5):1120-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcellular localization, modification and protein complex formation of the cdk-inhibitor p16 in Rb-functional and Rb-inactivated tumor cells.
  • The cdk-inhibitor p16 is a tumor suppressor gene that is inactivated in many forms of cancer.
  • Here, by subcellular fractionation of Rb-functional and Rb-inactivated cell lines, we show that p16 indeed is expressed in the cytoplasm as well as in the nucleus.
  • Samples of basal cell carcinoma and squamous cell carcinoma of the skin with either functional or non-functional Rb also exhibited at least two forms of p16.
  • [MeSH-minor] Cell Line, Tumor. Cell Nucleus / metabolism. Cyclin-Dependent Kinase 4 / metabolism. Cytoplasm / metabolism. Electrophoresis, Gel, Two-Dimensional. Humans. Protein Binding. Protein Transport

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16161044.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Retinoblastoma Protein; EC 2.7.11.22 / Cyclin-Dependent Kinase 4
  •  go-up   go-down


75. Lien HC, Lu YS, Shun CT, Yao YT, Chang WC, Cheng AL: Differential expression of glucocorticoid receptor in carcinomas of the human digestive system. Histopathology; 2008 Feb;52(3):314-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of glucocorticoid receptor in carcinomas of the human digestive system.
  • METHODS AND RESULTS: Specimens from 306 carcinomas of the human digestive tract were assayed for the expression of GR by immunohistochemistry.
  • GR expression was strong in oesophageal squamous epithelia, pancreatic islet cells and hepatocytes, but generally weak or negative in non-squamous epithelia.
  • Consistently, GR expression was found in a high percentage of oesophageal squamous cell carcinomas (SCC) (98.1%) and hepatocellular carcinomas (HCC) (92.9%), but rarely in gastric adenocarcinomas (7.4%) and not at all in colorectal adenocarcinomas (0%).
  • Dexamethasone (DEX) was found to confer chemoresistance in oesophageal SCC and HCC cells, suggesting that GR expression may be biologically important in some GR-expressing carcinomas.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Basosquamous / metabolism. Carcinoma, Squamous Cell / metabolism. Digestive System Neoplasms / metabolism. Receptors, Glucocorticoid / metabolism
  • [MeSH-minor] Ampulla of Vater / metabolism. Ampulla of Vater / pathology. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Cell Line, Tumor. Cell Survival / drug effects. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / mortality. Cholangiocarcinoma / pathology. Common Bile Duct Neoplasms / metabolism. Common Bile Duct Neoplasms / mortality. Common Bile Duct Neoplasms / pathology. DNA, Neoplasm / analysis. Dexamethasone / pharmacology. Drug Resistance, Neoplasm / drug effects. Humans. Immunoenzyme Techniques. Sequence Analysis, DNA. Survival Rate

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18269582.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Receptors, Glucocorticoid; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


76. de Haas ER, de Vijlder HC, van Reesema WS, van Everdingen JJ, Neumann HA: Quality of clinical practice guidelines in dermatological oncology. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1193-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We searched MEDLINE, PubMed, EMBASE and Cochrane literature and relevant websites of guidelines development programmes and the national dermatological society to identify evidence-based dermatological guidelines especially in the treatment of to basal cell carcinoma, squamous cell carcinoma and melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894704.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


77. Applebaum KM, Karagas MR, Hunter DJ, Catalano PJ, Byler SH, Morris S, Nelson HH: Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire. Environ Health Perspect; 2007 Aug;115(8):1231-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymorphisms in nucleotide excision repair genes, arsenic exposure, and non-melanoma skin cancer in New Hampshire.
  • UV damage is specifically repaired by nucleotide excision repair (NER), and common genetic variants in NER may increase risk for non-melanoma skin cancer (NMSC).
  • METHODS: Incident cases of basal and squamous cell carcinoma (BCC and SCC, respectively) were identified through a network of dermatologists and pathology laboratories across New Hampshire.
  • The analysis included 880 cases of BCC, 666 cases of SCC, and 780 controls.
  • RESULTS: There was an increased BCC risk associated with high arsenic exposure among those homozygous variant for XPA [odds ratio (OR) = 1.8; 95% confidence interval (CI), 0.9-3.7].
  • For XPD, having variation at both loci (312Asn and 751Gln) occurred less frequently among BCC and SCC cases compared with controls (OR = 0.8; 95% CI, 0.6-1.0) for both case groups.

  • MedlinePlus Health Information. consumer health - Arsenic.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC, ELEMENTAL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Health Perspect. 1998 Aug;106 Suppl 4:1047-50 [9703491.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:235-9 [10022259.001]
  • [Cites] Oncol Res. 1998;10(9):475-82 [10223623.001]
  • [Cites] Int J Cancer. 1999 May 17;81(4):555-9 [10225444.001]
  • [Cites] Toxicol Appl Pharmacol. 1999 Aug 15;159(1):65-75 [10448126.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Environ Health Perspect. 1999 Sep;107(9):727-9 [10464073.001]
  • [Cites] Prensa Med Argent. 1964 Oct 23;51:994-8 [14231402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Nov;13(11 Pt 1):1788-93 [15533908.001]
  • [Cites] Carcinogenesis. 2004 Dec;25(12):2433-41 [15333465.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Dec;13(12):2242-6 [15598786.001]
  • [Cites] Hum Mutat. 2005 Apr;25(4):353-9 [15776433.001]
  • [Cites] Cancer Lett. 2005 May 26;222(2):205-9 [15863269.001]
  • [Cites] Carcinogenesis. 2000 Apr;21(4):551-5 [10753184.001]
  • [Cites] Carcinogenesis. 2000 May;21(5):965-71 [10783319.001]
  • [Cites] J Natl Cancer Inst. 2000 Jun 7;92(11):874-97 [10841823.001]
  • [Cites] Pharmacology. 2000 Sep;61(3):212-27 [10971208.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1354-7 [11245433.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):559-65 [11257063.001]
  • [Cites] Carcinogenesis. 2001 Apr;22(4):593-7 [11285194.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3321-5 [11309287.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Apr;10(4):355-60 [11319176.001]
  • [Cites] Carcinogenesis. 2001 Jun;22(6):899-904 [11375896.001]
  • [Cites] Mutat Res. 2001 Jul 1;478(1-2):159-68 [11406180.001]
  • [Cites] Carcinogenesis. 2001 Aug;22(8):1185-8 [11470747.001]
  • [Cites] Toxicol Appl Pharmacol. 2001 Dec 1;177(2):132-48 [11740912.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):152-5 [11782372.001]
  • [Cites] Carcinogenesis. 2002 Apr;23(4):599-603 [11960912.001]
  • [Cites] Int J Hyg Environ Health. 2002 Mar;205(1-2):85-94 [12018020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):993-7 [12376498.001]
  • [Cites] Mutat Res. 2002 Nov 30;509(1-2):165-74 [12427537.001]
  • [Cites] J Invest Dermatol. 2003 Jan;120(1):48-55 [12535197.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):263-8 [12569548.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Toxicol Lett. 2003 Jul 20;143(2):123-31 [12749816.001]
  • [Cites] Mutat Res. 2003 Dec 10;533(1-2):37-65 [14643412.001]
  • [Cites] Mutagenesis. 2004 Mar;19(2):143-8 [14981161.001]
  • [Cites] Carcinogenesis. 2004 May;25(5):729-34 [14688016.001]
  • [Cites] Br J Cancer. 2004 Oct 18;91(8):1604-9 [15381933.001]
  • [Cites] J Natl Cancer Inst. 1968 Mar;40(3):453-63 [5644201.001]
  • [Cites] Beitr Pathol. 1974 Apr;151(4):384-400 [4838015.001]
  • [Cites] Can Med Assoc J. 1975 Sep 6;113(5):396-401 [125622.001]
  • [Cites] Am J Epidemiol. 1976 Dec;104(6):609-20 [998608.001]
  • [Cites] Hum Toxicol. 1983 Jan;2(1):121-33 [6840787.001]
  • [Cites] Cancer Res. 1985 Nov;45(11 Pt 2):5895-9 [4053060.001]
  • [Cites] J Mol Biol. 1987 Aug 20;196(4):947-50 [3681984.001]
  • [Cites] J Clin Epidemiol. 1989;42(4):317-24 [2723692.001]
  • [Cites] Mol Toxicol. 1989 Winter;2(1):1-9 [2615768.001]
  • [Cites] Biol Trace Elem Res. 1989 Jul-Sep;21:373-81 [2484616.001]
  • [Cites] Biol Met. 1991;4(4):197-200 [1777354.001]
  • [Cites] Mutagenesis. 1992 Jan;7(1):51-5 [1635456.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7 [8220096.001]
  • [Cites] Mutat Res. 2005 Jul 1;574(1-2):105-11 [15914210.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):209-14 [15936590.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1539-44 [15941969.001]
  • [Cites] Mutat Res. 2006 Jun;612(3):215-46 [16574468.001]
  • [Cites] Environ Health Perspect. 2006 Aug;114(8):1193-8 [16882524.001]
  • [Cites] Carcinogenesis. 2006 Aug;27(8):1670-5 [16513681.001]
  • [Cites] Carcinogenesis. 2007 Mar;28(3):672-6 [17050553.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 2004;84:1-477 [15645577.001]
  • [Cites] Am J Epidemiol. 1994 Oct 1;140(7):598-607 [7942760.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):109-14 [7819025.001]
  • [Cites] Mamm Genome. 1996 Aug;7(8):563-74 [8679005.001]
  • [Cites] Carcinogenesis. 1997 Feb;18(2):399-405 [9054635.001]
  • [Cites] Mutat Res. 1997 Jun;386(3):345-51 [9219571.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96 [9264271.001]
  • [Cites] Epidemiology. 1997 Sep;8(5):545-50 [9270957.001]
  • [Cites] Trends Biochem Sci. 1998 Jan;23(1):1-4 [9478126.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):604-8 [9485007.001]
  • [Cites] Mutat Res. 1998 Feb;407(1):25-34 [9539978.001]
  • (PMID = 17687452.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA057494; United States / NCI NIH HHS / CA / R01CA082354; United States / NIEHS NIH HHS / ES / P42 ES007373; United States / NIEHS NIH HHS / ES / T32 ES07155; United States / NIEHS NIH HHS / ES / P42 ES07373; United States / NCI NIH HHS / CA / R01CA57494; United States / NIEHS NIH HHS / ES / T32 ES007155; United States / NCI NIH HHS / CA / R01 CA082354
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Environmental Pollutants; 0 / XPA protein, human; 0 / Xeroderma Pigmentosum Group A Protein; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; N712M78A8G / Arsenic
  • [Other-IDs] NLM/ PMC1940098
  •  go-up   go-down


78. Cunneen TS, Yong JL, Benger R: Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential. Clin Exp Ophthalmol; 2008 Jul;36(5):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung metastases in a case of metatypical basal cell carcinoma of the eyelid: an illustrative case and literature review to heighten vigilance of its metastatic potential.
  • Basal cell carcinoma (BCC) is an extremely common malignancy; however, unlike other skin cancers, they very rarely metastasize.
  • Here we present an unusual case of metatypical BCC of the eyelid which metastasized to the lung nine years after initial surgical treatment.
  • We include a review of the literature regarding metastatic BCC and suggest that metatypical features in primary BCC should prompt careful patient monitoring and consideration of adjuvant treatment at the time of diagnosis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Eyelid Neoplasms / pathology. Lung Neoplasms / pathology. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for metatypical basal cell carcinoma .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18925916.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Number-of-references] 13
  •  go-up   go-down


79. Marioni G, Ottaviano G, Marchese-Ragona R, Giacomelli L, Bertolin A, Zanon D, Marino F, Staffieri A: High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma. Acta Otolaryngol; 2006 Feb;126(2):197-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma.
  • CONCLUSION: Nuclear expression of survivin should be studied as a promising marker of higher-risk laryngeal basaloid squamous cell carcinomas (BSCCs), which can then be treated more aggressively and followed more closely.
  • The regulation of apoptotic cell death has a profound effect on the pathogenesis and progression of malignancies.
  • Nuclear survivin expression was significantly higher in BSCCs associated with disease recurrence and poor prognosis (p=0.02).
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Basosquamous / metabolism. Laryngeal Neoplasms / metabolism. Microtubule-Associated Proteins / analysis. Neoplasm Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Case-Control Studies. Humans. Immunohistochemistry. Inhibitor of Apoptosis Proteins. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Prognosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428200.001).
  • [ISSN] 0001-6489
  • [Journal-full-title] Acta oto-laryngologica
  • [ISO-abbreviation] Acta Otolaryngol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Biomarkers, Tumor; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


80. Petrella LI, Valle HA, Issa PR, Martins CJ, Pereira WC, Machado JC: Study of cutaneous cell carcinomas ex vivo using ultrasound biomicroscopic images. Skin Res Technol; 2010 Nov;16(4):422-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of cutaneous cell carcinomas ex vivo using ultrasound biomicroscopic images.
  • In this sense, several studies are being conducted for the measurement of cutaneous tumor sizes and for the evaluation of their response to therapeutic procedures.
  • The present work was conducted to analyze the ability of UBM to identify diverse histological structures associated with cutaneous carcinomas ex vivo regarding the evaluation of the technique as a diagnostic tool that could, eventually, improve the patient's healthcare protocol.
  • METHODS: Ex vivo human tissue samples, corresponding to basal cell carcinoma and squamous cell carcinoma cases, were studied.
  • RESULTS: The histological components present in the tumors were identified by variations in the echogenicity level for several of the studied cases and particular characteristics were observed for the different tumor types.
  • CONCLUSION: The possibility of differentiating the histological components associated with cutaneous carcinomas indicates the potential use of UBM for diagnostic applications.
  • [MeSH-major] Bowen's Disease / ultrasonography. Carcinoma, Basal Cell / ultrasonography. Carcinoma, Squamous Cell / ultrasonography. Dermoscopy / methods. Skin Neoplasms / ultrasonography. Ultrasonography / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 21039907.001).
  • [ISSN] 1600-0846
  • [Journal-full-title] Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)
  • [ISO-abbreviation] Skin Res Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


81. Testori A, Tosti G, Martinoli C, Spadola G, Cataldo F, Verrecchia F, Baldini F, Mosconi M, Soteldo J, Tedeschi I, Passoni C, Pari C, Di Pietro A, Ferrucci PF: Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach. Dermatol Ther; 2010 Nov-Dec;23(6):651-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach.
  • Electroporation uses pulsed, high-intensity electric fields to temporarily increase cell membrane permeability by creation of pores, through which small molecules, such as chemotherapeutic agents, can diffuse inside cells before they reseal.
  • ECT has already been proven to be effective in diverse tumor histotypes, including melanoma and basal and squamous cell carcinoma, Kaposi sarcoma, and breast cancer, also in those cases nonresponding to classical chemotherapies or other loco-regional treatment modalities, with a good safety profile.
  • ECT can be proposed as loco-regional therapy for disseminated cutaneous and subcutaneous tumor lesions as alternative treatment modality to conventional therapies or as palliative care, in order to improve patients' quality of life.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Electrochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Animals. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Humans. Skin / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley Periodicals, Inc.
  • (PMID = 21054709.001).
  • [ISSN] 1529-8019
  • [Journal-full-title] Dermatologic therapy
  • [ISO-abbreviation] Dermatol Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


82. Caccialanza M, Piccinno R, Kolesnikova L, Gnecchi L: Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients. Int J Dermatol; 2005 Jun;44(6):513-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy of skin carcinomas of the pinna: a study of 115 lesions in 108 patients.
  • BACKGROUND: The possibility of treating skin carcinomas of the pinna with radiotherapy is somewhat under discussion and scarcely known.
  • Therefore the aim of the study was to evaluate the effectiveness and safety of dermatologic radiotherapy in a series of patients affected by basal or squamous cell carcinoma of the pinna.
  • METHODS: A retrospective study was performed on 108 patients affected by 115 carcinomas of the pinna (99 basal cell carcinomas, 16 squamous cell carcinomas) without involvement of the external auditory canal.
  • During follow up a relapse was observed in 12 lesions (all basal cell carcinomas): nine central and three marginal to the irradiation field.
  • CONCLUSIONS: The results obtained confirm the possibility of treating epithelial skin neoplasms of the pinna with dermatologic radiotherapy, which can afford high-remission percentages without damaging cartilaginous tissue.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Ear Neoplasms / radiotherapy. Ear, External. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Aged. Aged, 80 and over. Esthetics. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / therapy. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15941445.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Thomas L, Dalle S: [Pathology of the eyelid in elderly patients]. J Fr Ophtalmol; 2006 Jun;29(6):672-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Illustrated review centered on diagnosis of the usual aspects and pitfalls of eyelid pathology divided into semiological chapters (tumors, blisters, erythema, etc.).
  • It is mainly centered on skin cancers (basal cell carcinoma, squamous cell carcinoma, adnexal carcinomas, and melanoma).
  • A number of rare diseases deserve mention since their presence could lead to the diagnosis of internal or systemic diseases (dermatomyositis, necrobiotic xanthogranuloma, Erdheim-Chester, etc.).
  • In such conditions, early diagnosis is often based on the observation of isolated periocular symptoms.
  • CONCLUSIONS: Even though topographic dermatology is a somewhat reductive vision of skin diseases, pathology of the eyelids deserves special mention because of its polymorphism as well as its diagnostic and/or therapeutic significance.
  • [MeSH-major] Eyelid Diseases / diagnosis
  • [MeSH-minor] Aged. Eyelid Neoplasms / diagnosis. Humans

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16885900.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 123
  •  go-up   go-down


84. McGuire JF, Ge NN, Dyson S: Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior. Am J Otolaryngol; 2009 Mar-Apr;30(2):121-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonmelanoma skin cancer of the head and neck I: histopathology and clinical behavior.
  • Non-Melanoma skin cancer (NMSC) is the most commonly encountered malignancy in almost every area of practice, but the cases that present to an Otolaryngology practice will be advanced in nature.
  • The major subtypes of NMSC include basal cell carcinoma, squamous cell carcinoma, dermatofibrosarcoma protuberans, merkel cell carcinoma, and adnexal malignancies.
  • [MeSH-major] Carcinoma / pathology. Dermatofibrosarcoma / pathology. Head and Neck Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Neoplasm Metastasis. Organ Transplantation / adverse effects

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19239954.001).
  • [ISSN] 1532-818X
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 123
  •  go-up   go-down


85. Aboutalebi S, Strickland FM: Immune protection, natural products, and skin cancer: is there anything new under the sun? J Drugs Dermatol; 2006 Jun;5(6):512-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immune protection, natural products, and skin cancer: is there anything new under the sun?
  • Non-melanoma skin cancers such as squamous cell carcinoma and basal cell carcinoma are the most common types of human neoplasms, representing one third of all new malignancies diagnosed in the US.
  • Ultraviolet (UV) radiation from the sun is a major cause of non-melanoma skin cancer in humans.
  • Aside from the mutagenic effects of UV radiation, there are suggestions from clinical studies and evidence in animal models that the immune system plays an important role in preventing skin cancer development and progression, and is suppressed by cutaneous exposure to UV radiation.
  • In this article, we review the research on new and existing agents that are being developed to protect the skin immune response from suppression by UV radiation.
  • [MeSH-major] Aloe. Antioxidants / therapeutic use. Carcinoma, Basal Cell. Phytotherapy. Skin Neoplasms. Ultraviolet Rays / adverse effects

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Sodium ascorbate .
  • Hazardous Substances Data Bank. L-Ascorbic Acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16774102.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Flavonoids; 0 / Phenols; 0 / Polyphenols; 1406-18-4 / Vitamin E; PQ6CK8PD0R / Ascorbic Acid
  • [Number-of-references] 67
  •  go-up   go-down


86. Thosani MK, Marghoob A, Chen CS: Current progress of immunostains in Mohs micrographic surgery: a review. Dermatol Surg; 2008 Dec;34(12):1621-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mohs micrographic surgery is often considered the treatment of choice for a variety of skin malignancies.
  • In recent years, the application of immunostaining techniques has facilitated the successful removal of a number of common and less common cutaneous malignancies, including basal cell carcinoma, squamous cell carcinoma, malignant melanoma, dermatofibrosarcoma protuberans, microcystic adnexal carcinoma, sebaceous carcinoma, atypical fibroxanthoma, extramammary Paget's disease, and even sarcomas.
  • Immunostains highlight the tumor cells and allow the Mohs surgeons to pinpoint and eliminate the residual tumor at the surgical margin.
  • It is especially helpful when a tumor presents with subtle or nonspecific histologic features or when a tumor is masked in a pocket of dense inflammation.
  • [MeSH-major] Mohs Surgery / methods. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Staining and Labeling / methods

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018832.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 127
  •  go-up   go-down


87. Basile J, Thiers B, Maize J Sr, Lathers DM: Chemokine receptor expression in non-melanoma skin cancer. J Cutan Pathol; 2008 Jul;35(7):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemokine receptor expression in non-melanoma skin cancer.
  • Prior studies have shown that in metastatic melanoma and squamous cell carcinoma of the head and neck upregulation of CXC (alpha) chemokine receptor (CXCR)4 and CC (beta) chemokine receptor (CCR)7 expression is accompanied by downregulation of the chemokine receptor CCR6.
  • However, the expression patterns of CCR6, CCR7 and CXCR4 in non-melanoma skin cancer have yet to be elucidated.
  • METHODS: The expression patterns of CCR6, CCR7 and CXCR4 were determined using an immunohistochemical approach on formalin-fixed, paraffin-embedded normal, pre-cancerous actinic (solar) keratosis, squamous cell carcinoma and basal cell carcinoma tissues.
  • RESULTS: Analysis of chemokine receptor expression showed downregulation of CCR6 and upregulation of CCR7 and CXCR4 in potentially metastatic non-melanoma skin cancer, invasive squamous cell carcinoma, but this pattern did not exist in non-melanoma skin cancer with no metastatic potential, basal cell carcinoma; or actinic keratosis, when compared with normal skin.
  • CONCLUSIONS: Chemokine receptor expression may influence the biological behavior of non-melanoma skin cancer.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis / metabolism. Receptors, CCR6 / metabolism. Receptors, CCR7 / metabolism. Receptors, CXCR4 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Analysis of Variance. Biomarkers / metabolism. Down-Regulation. Humans. Immunohistochemistry. Neoplasm Metastasis / physiopathology. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Skin / metabolism. Skin / pathology. Staining and Labeling. Ultraviolet Rays / adverse effects. Up-Regulation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312436.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCR6 protein, human; 0 / CCR7 protein, human; 0 / CXCR4 protein, human; 0 / Receptors, CCR6; 0 / Receptors, CCR7; 0 / Receptors, CXCR4
  •  go-up   go-down


88. Chovanec M, Smetana K Jr, Plzák J, Betka J, Plzáková Z, Stork J, Hrdlicková E, Kuwabara I, Dvoránková B, Liu FT, Kaltner H, André S, Gabius HJ: Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia. Prague Med Rep; 2005;106(2):209-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new diagnostic markers in pathology by focus on growth-regulatory endogenous lectins. The case study of galectin-7 in squamous epithelia.
  • Lectins represent one of pivotal regulators of the cell proliferation The potential of galectin-7 as a new prognostic marker was studied in normal and transformed squamous epithelia of both ectodermal (epidermis, cornea vs. trichoepithelioma, basal and squamous cell carcinoma) and endodermal (vocal fold epithelium vs. carcinoma) origin.
  • Its expression is significantly reduced in malignant cells, thus galectin-7 might be a differentiation marker of epithelial malignancies.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Epithelium / chemistry. Galectins / analysis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Cell Division / physiology. Cells, Cultured. Humans. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315769.001).
  • [ISSN] 1214-6994
  • [Journal-full-title] Prague medical report
  • [ISO-abbreviation] Prague Med Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Czech Republic
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Galectins; 0 / LGALS7 protein, human
  •  go-up   go-down


89. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST: Mast cells and cutaneous malignancies. Mod Pathol; 2006 Jan;19(1):149-59
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This paper reviews the role of mast cells in the development and progression of basal cell carcinoma, squamous cell carcinoma and malignant melanoma.
  • Upon irradiation of the skin, trans-urocanic acid in the epidermis isomerizes to cis-urocanic acid, which stimulates neuropeptide release from neural c-fibers.
  • These neuropeptides in turn trigger histamine secretion from mast cells, leading to suppression of the cellular immune system. (2) Angiogenesis: Mast cells are the major source of vascular endothelial growth factor in basal cell carcinoma and malignant melanoma.
  • Vascular endothelial growth factor is one of the most potent angiogenic factors, which also induces leakage of other angiogenic factors across the endothelial cell wall into the matrix.
  • Mast cell proteases reorganize the stroma to facilitate endothelial cell migration.
  • As well, heparin, the dominant mast cell proteoglycan, assists in blood-borne metastasis. (3) Degradation of extracellular matrix: Through its own proteases, and indirectly via interaction with other cells, mast cells participate in degradation of the matrix, which is required for tumor spread. (4) Mitogenesis: Mast cell mediators including fibroblast growth factor-2 and interleukin-8 are mitogenic to melanoma cells.
  • Emerging data, however, also suggest that mast cells might, in fact, have opposing roles in tumor biology, and the microenvironment could polarize mast cells to possess either promoting or inhibitory effects on tumors.
  • [MeSH-major] Mast Cells / physiology. Skin Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Basal Cell / blood. Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / blood supply. Carcinoma, Squamous Cell / pathology. Humans. Melanoma / blood. Melanoma / blood supply. Melanoma / pathology. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / blood

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258517.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 71
  •  go-up   go-down


90. Krathen MS, Gottlieb AB, Mease PJ: Pharmacologic immunomodulation and cutaneous malignancy in rheumatoid arthritis, psoriasis, and psoriatic arthritis. J Rheumatol; 2010 Nov;37(11):2205-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: It is unclear if skin cancer risk is affected by the use of immunomodulatory medications in rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA).
  • METHODS: The English language literature on PubMed was searched with a combination of phrases, including "malignancy," "skin cancer," "squamous cell carcinoma," "basal cell carcinoma," "melanoma," "psoriasis," "psoriatic arthritis," and "rheumatoid arthritis" in addition to the generic names of a variety of common immunomodulatory drugs.
  • Treatment with tumor necrosis factor inhibitors increases the rates of non-melanoma skin cancer (NMSC) in RA and psoriasis.
  • Methotrexate may increase the risk of malignant melanoma in patients with RA and the risk of NMSC in psoriasis.
  • More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
  • [MeSH-major] Arthritis, Psoriatic / therapy. Arthritis, Rheumatoid / therapy. Immunosuppression / adverse effects. Psoriasis / therapy. Skin Neoplasms / etiology


91. Vasconcelos HM Jr, Almeida AL, Sagawa A, Carvalho RM, Avila MP: [An advanced case of basosquamous carcinoma of the orbit: case report]. Arq Bras Oftalmol; 2009 Nov-Dec;72(6):819-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of basosquamous carcinoma of the orbit: case report].
  • [Transliterated title] Carcinoma basoescamoso avançado de órbita: relato de caso.
  • Basosquamous carcinoma is a rare tumor with features of both basal cell and squamous cell carcinoma, linked by a transition area.
  • It is a rare epithelial neoplasm with a tendency for local recurrence.
  • It also has a high incidence of distant metastasis, a condition that differentiates it from the basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basosquamous / pathology. Orbital Neoplasms / pathology. Patient Compliance
  • [MeSH-minor] Disease Progression. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20098906.001).
  • [ISSN] 1678-2925
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


92. Decara JM, Aguilera J, Abdala R, Sánchez P, Figueroa FL, Herrera E: Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin. Exp Dermatol; 2008 Oct;17(10):806-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening of urocanic acid isomers in human basal and squamous cell carcinoma tumors compared with tumor periphery and healthy skin.
  • This immunomodulation has been recognized as an important factor related to skin cancer development.
  • This is the first time that UCA isomers have been measured in epidermis of skin biopsies from patients with squamous cell carcinoma (SCC) and with basal cell carcinoma (BCC) and compared with the tumor periphery and biopsies of healthy photoexposed and non-photoexposed skin as controls.
  • Analysis of UCA in healthy skin showed significant increase in total UCA content in non-photoexposed body sites compared with highly exposed skins.
  • No differences were found in total UCA concentration between the tumor samples and healthy photoexposed skin.
  • Higher levels of cUCA were detected in SCC biopsies (44% of total UCA) compared with samples of BCC and that of healthy photoexposed skin (30%).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Epidermis / radiation effects. Skin Neoplasms / pathology. Ultraviolet Rays. Urocanic Acid / metabolism

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312386.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] G8D26XJJ3B / Urocanic Acid
  •  go-up   go-down


93. Wimmer E, Kraehn-Senftleben G, Issing WJ: HER3 expression in cutaneous tumors. Anticancer Res; 2008 Mar-Apr;28(2A):973-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In order to elucidate the role of the receptor tyrosine kinase HER3, the expression characteristics in different tissues of cutaneous malignancies and in normal skin were compared.
  • MATERIALS AND METHODS: In this study HER3 expression was evaluated by RT-PCR analysis and immunohistochemistry from different tissue specimens of cutaneous tumors like nevi, primary malignant melanomas, basal cell carcinoma, squamous cell carcinoma and malignant melanoma metastases and normal skin samples and graded into weak, moderate and strong expression.
  • Associations of tumor thickness in these specimens with HER3 expressions were also analyzed.
  • RESULTS: HER3 expression was found in 63% (10/16) of the basal cell carcinomas, in 4/5 of squamous cell carcinomas and in one Merkel cell carcinoma.
  • Within the group of different malignant melanomas, HER3 expression was detected in 35% of the nodular malignant melanomas (6/17) and in 9/19 of the superficial spreading melanomas, including 2 lentigo malignant melanomas.
  • The majority of melanomas with a higher tumor thickness expressed HER3, and 85% of melanoma metastasis were HER3-positive.
  • CONCLUSION: HER3 expression was associated with hyperproliferate tumor stages and suggested that HER3 expression could reflect an increased malignant potential in cutaneous lesions.
  • [MeSH-major] Skin Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Basal Cell / genetics. Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Humans. Immunohistochemistry. Melanoma / genetics. Melanoma / metabolism. Neoplasm Metastasis. Nevus. Receptor, ErbB-3 / genetics. Receptor, ErbB-3 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Skin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507044.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


94. Zhang H, Yan J, Li Y, Zhang P: Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature. Yan Ke Xue Bao; 2005 Sep;21(3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucoepidermoid carcinoma of the eyelid: a case report and review of the literature.
  • PURPOSE: To report the clinical features, therapeutic method, and histopathological findings of a case of mucoepidermoid carcinoma in the lower eyelid and review the literature about the mucoepidermoid carcinoma arising from the eye.
  • RESULTS: An 88-year-old man developed a painless, indurated nodule in the left lower eyelid for two years and ulceration of the skin existed for a year.
  • He underwent tumor resection and reconstruction of the eyelid.
  • By histopathology, tumor cells showed an admixture of epidermoid and mucus-secreting cells, which was consistent with mucoepidermoid carcinoma.
  • Mucoepidermoid carcinoma is a common malignant tumor of the salivary glands, but rare in the eye tissues among which conjunctiva and lacrimal gland are most commonly involved.
  • It has a higher degree of malignancy than basal cell carcinoma and squamous cell carcinoma.
  • CONCLUSIONS: Mucoepidermoid carcinoma arising from the eye is rare and has a high degree of malignancy.
  • It should be differentiated from other neoplasms such as basal cell carcinoma and squamous cell carcinoma.

  • Genetic Alliance. consumer health - Mucoepidermoid carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17162853.001).
  • [ISSN] 1000-4432
  • [Journal-full-title] Yan ke xue bao = Eye science
  • [ISO-abbreviation] Yan Ke Xue Bao
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 23
  •  go-up   go-down


95. Leibeling D, Laspe P, Emmert S: Nucleotide excision repair and cancer. J Mol Histol; 2006 Sep;37(5-7):225-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • NER consists of a multistep process in which the DNA lesion is recognized and demarcated by DNA unwinding.
  • XP patients show severe sun sensitivity, freckling in sun exposed skin, and develop skin cancers already during childhood.
  • Clinical symptoms of TTD patients include sun sensitivity, freckling in sun exposed skin areas, and brittle sulfur-deficient hair.
  • In contrast to XP patients, CS and TTD patients are not skin cancer prone.
  • Studying these syndromes can increase the knowledge of skin cancer development including cutaneous melanoma as well as basal and squamous cell carcinoma in general that may lead to new preventional and therapeutic anticancer strategies in the normal population.

  • MedlinePlus Health Information. consumer health - Hair Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cells Tissues Organs. 2004;177(3):189-98 [15388993.001]
  • [Cites] Arch Dermatol. 1980 Dec;116(12):1375-84 [7458366.001]
  • [Cites] Skin Pharmacol. 1994;7(5):257-61 [8054207.001]
  • [Cites] EMBO J. 1999 Jun 15;18(12 ):3491-501 [10369688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Aug 1;90(15):7260-4 [8346243.001]
  • [Cites] Photochem Photobiol. 1993 Sep;58(3):450-4 [8234481.001]
  • [Cites] Basic Life Sci. 1990;53:149-60 [2282032.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6090-5 [10339546.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Jan;8(1):77-81 [9950243.001]
  • [Cites] Mol Gen Genet. 1991 Aug;228(1-2):153-9 [1679524.001]
  • [Cites] Biochemistry. 1992 Jul 28;31(29):6794-800 [1637815.001]
  • [Cites] Exp Dermatol. 2003 Oct;12(5):529-36 [14705792.001]
  • [Cites] J Dtsch Dermatol Ges. 2006 Sep;4(9):721-31 [16928240.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1085-90 [15731165.001]
  • [Cites] Mol Cell Biol. 1995 Jan;15(1):290-7 [7799936.001]
  • [Cites] Cold Spring Harb Symp Quant Biol. 1994;59:317-29 [7587084.001]
  • [Cites] Biochimie. 1999 Jan-Feb;81(1-2):15-25 [10214906.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Feb 15;90(4):1614-8 [8434025.001]
  • [Cites] J Invest Dermatol. 1996 Oct;107(4):647-53 [8823375.001]
  • [Cites] EMBO J. 1996 Apr 1;15(7):1666-77 [8612591.001]
  • [Cites] Hautarzt. 2002 Mar;53(3):167-73 [11974587.001]
  • [Cites] Exp Dermatol. 1996 Jun;5(3):173-80 [8840158.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8658-63 [9238033.001]
  • [Cites] Proc Natl Acad Sci U S A. 1975 Oct;72(10):4071-5 [172893.001]
  • [Cites] Br J Dermatol. 1993 Apr;128(4):384-7 [8494750.001]
  • [Cites] Am J Med Genet. 1992 Jan 1;42(1):68-84 [1308368.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):291-300 [11443545.001]
  • [Cites] J Invest Dermatol. 1994 Nov;103(5 Suppl):96S-101S [7963692.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):465-8 [9641488.001]
  • [Cites] Science. 1999 Dec 3;286(5446):1897-905 [10583946.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):815-20 [11773631.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3116-21 [9096355.001]
  • [Cites] Am J Hum Genet. 1998 Jan;62(1):77-85 [9443879.001]
  • [Cites] Eur J Hum Genet. 2005 Feb;13(2):253-5 [15494739.001]
  • [Cites] Mol Cell. 1999 Jan;3(1):33-42 [10024877.001]
  • [Cites] J Biol Chem. 1993 Oct 5;268(28):21293-300 [8407967.001]
  • [Cites] Biochimie. 1999 Jan-Feb;81(1-2):39-44 [10214908.001]
  • [Cites] J Cell Physiol. 2002 Apr;191(1):28-41 [11920679.001]
  • [Cites] Nature. 1993 May 13;363(6425):114-5 [8483493.001]
  • [Cites] J Invest Dermatol. 1998 Nov;111(5):791-6 [9804340.001]
  • [Cites] J Am Acad Dermatol. 1994 Feb;30(2 Pt 2):329-35 [8294592.001]
  • [Cites] Science. 1997 Feb 14;275(5302):990-3 [9020084.001]
  • [Cites] Am J Med Genet A. 2004 Jul 30;128A(3):235-45 [15216543.001]
  • [Cites] Hum Mol Genet. 2001 Oct 15;10(22):2539-47 [11709541.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):505-9 [12663511.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):714-9 [15220921.001]
  • [Cites] J Biol Chem. 1997 Mar 21;272(12):7570-3 [9065408.001]
  • [Cites] Clin Dermatol. 1985 Jan-Mar;3(1):33-69 [3833325.001]
  • [Cites] Neurology. 2000 Nov 28;55(10):1442-9 [11185579.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):10103-9 [11124949.001]
  • [Cites] Carcinogenesis. 2001 Mar;22(3):403-8 [11238179.001]
  • [Cites] Hum Genet. 1996 Apr;97(4):418-23 [8834235.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2151-6 [10681431.001]
  • [Cites] Nucleic Acids Res. 1992 Sep 25;20(18):4761-4 [1357629.001]
  • [Cites] Science. 1996 Jul 5;273(5271):63-7 [8658197.001]
  • [Cites] Carcinogenesis. 2002 Feb;23(2):295-9 [11872635.001]
  • [Cites] Arch Dermatol. 1987 Feb;123(2):241-50 [3545087.001]
  • [Cites] J Invest Dermatol. 1972 Mar;58(3):124-8 [5013606.001]
  • [Cites] Cancer Surv. 1985;4(3):601-24 [3916657.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2002 Jun;18(3):109-16 [12207672.001]
  • [Cites] JAMA. 1988 Jul 15;260(3):384-8 [3379749.001]
  • [Cites] Am J Hum Genet. 1993 Oct;53(4):817-21 [8213812.001]
  • [Cites] J Invest Dermatol. 1995 Jun;104(6):933-6 [7769261.001]
  • [Cites] Jpn J Cancer Res. 1987 Nov;78(11):1135-43 [3121549.001]
  • [Cites] Mol Med Today. 1999 Feb;5(2):86-94 [10200950.001]
  • [Cites] Nucleic Acids Res. 1993 Mar 11;21(5):1055-9 [8464692.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 2001 Oct;17(5):203-12 [11555329.001]
  • [Cites] Hum Mol Genet. 1994 Jun;3(6):963-7 [7951246.001]
  • [Cites] Photochem Photobiol. 1998 Sep;68(3):243-56 [9747581.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9463-8 [9256505.001]
  • [Cites] Mutat Res. 1991 Jul;255(1):1-9 [2067547.001]
  • [Cites] Photochem Photobiol. 1991 Nov;54(5):753-60 [1665912.001]
  • [Cites] Mutat Res. 1982 Dec;106(2):347-56 [6185841.001]
  • [Cites] Ann Intern Med. 1974 Feb;80(2):221-48 [4811796.001]
  • [Cites] Hum Genet. 1986 Oct;74(2):107-12 [3770739.001]
  • [Cites] Nat Genet. 1994 Jun;7(2):189-94 [7920640.001]
  • [Cites] Cell. 2000 Apr 14;101(2):159-71 [10786832.001]
  • [Cites] Science. 2001 Feb 16;291(5507):1284-9 [11181991.001]
  • [Cites] Photochem Photobiol. 1989 Jun;49(6):805-19 [2672059.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4227-31 [1638536.001]
  • [Cites] Science. 1992 Apr 24;256(5056):523-6 [1575827.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1790-5 [10660687.001]
  • [Cites] J Invest Dermatol. 1994 Apr;102(4):485-9 [8151125.001]
  • [Cites] Mol Cell Biol. 2005 Nov;25(22):9784-92 [16260596.001]
  • [Cites] J Natl Cancer Inst. 2003 Feb 19;95(4):308-15 [12591987.001]
  • [Cites] Nucleic Acids Res. 2001 Apr 1;29(7):1443-52 [11266544.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):972-82 [12060391.001]
  • [Cites] Science. 1999 Jul 9;285(5425):263-5 [10398605.001]
  • [Cites] Am J Hum Genet. 1997 Feb;60(2):320-9 [9012405.001]
  • [Cites] Nucleic Acids Res. 2002 Aug 15;30(16):3624-31 [12177305.001]
  • [Cites] J Invest Dermatol. 2000 Jan;114(1):34-9 [10620112.001]
  • [Cites] Brain. 1991 Jun;114 ( Pt 3):1335-61 [2065254.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4103-7 [8797573.001]
  • [Cites] Oncogene. 2000 Sep 28;19(41):4721-8 [11032022.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1415-21 [286113.001]
  • [Cites] Carcinogenesis. 2006 Jan;27(1):84-94 [16081512.001]
  • [Cites] Mol Cell Biol. 1991 Aug;11(8):4128-34 [1649389.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):15-23 [11156600.001]
  • [Cites] Methods Mol Biol. 1999;113:133-46 [10443416.001]
  • [Cites] Photodermatol Photoimmunol Photomed. 1996 Jun;12(3):122-30 [8956362.001]
  • [Cites] J Invest Dermatol. 1994 Oct;103(4):461-8 [7930668.001]
  • [Cites] Am J Hum Genet. 2003 Dec;73(6):1217-39 [14639525.001]
  • [Cites] Cutis. 2004 Nov;74(5 Suppl):10-3 [15603216.001]
  • [Cites] Nature. 1999 Jun 17;399(6737):700-4 [10385124.001]
  • [Cites] J Virol. 1984 Dec;52(3):846-56 [6092716.001]
  • [Cites] J Am Acad Dermatol. 2001 Jun;44(6):891-920; quiz 921-4 [11369901.001]
  • [Cites] J Biol Chem. 1994 Dec 30;269(52):32709-12 [7806489.001]
  • [Cites] Ann Neurol. 1986 Jul;20(1):70-5 [3740815.001]
  • [Cites] Lancet. 2001 Mar 24;357(9260):926-9 [11289350.001]
  • [Cites] J Invest Dermatol. 2002 Feb;118(2):344-51 [11841555.001]
  • [Cites] Hum Genet. 1997 Dec;101(3):317-22 [9439661.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):453-60 [10688865.001]
  • [Cites] Nat Med. 2001 Aug;7(8):961-6 [11479630.001]
  • [Cites] Mutat Res. 1996 Feb 15;362(2):209-11 [8596540.001]
  • [Cites] Am J Hum Genet. 2000 Apr;66(4):1221-8 [10739753.001]
  • [Cites] Photochem Photobiol. 1996 Apr;63(4):356-7 [8934734.001]
  • [Cites] Nature. 2001 May 17;411(6835):366-74 [11357144.001]
  • [Cites] Curr Biol. 1999 Mar 11;9(5):273-6 [10074455.001]
  • [Cites] J Biol Chem. 1991 Nov 5;266(31):20940-5 [1939143.001]
  • (PMID = 16855787.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 150
  •  go-up   go-down


96. Costantino D, Lowe L, Brown DL: Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature. J Plast Reconstr Aesthet Surg; 2006;59(4):424-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basosquamous carcinoma-an under-recognized, high-risk cutaneous neoplasm: case study and review of the literature.
  • Basosquamous carcinoma of the skin is a relatively rare cutaneous neoplasm that has been shown to have significant metastatic potential.
  • Histopathologists debate whether these lesions arise de novo or differentiate from pre-existing basal cell carcinomas.
  • We present a case in which a longstanding lesion initially diagnosed as basal cell carcinoma was later found to have basosquamous histology and regional metastases.
  • Review of the literature reveals a metastatic rate greater than that of basal cell and squamous cell carcinoma, and identifies several important characteristics that impact prognosis after surgical resection.
  • For physicians treating carcinomas of the skin, it is important to understand the natural history and proper treatment of this aggressive neoplasm.
  • [MeSH-major] Carcinoma, Basosquamous / diagnosis. Carcinoma, Squamous Cell / diagnosis. Foot Diseases / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis / diagnosis. Male. Middle Aged


97. Wells MJ, Taylor RS: Mohs micrographic surgery for penoscrotal malignancy. Urol Clin North Am; 2010 Aug;37(3):403-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific penoscrotal neoplasias discussed in this article include invasive and in situ squamous cell carcinoma, basal cell carcinoma, extramammary Paget disease, and granular cell tumor.
  • [MeSH-minor] Carcinoma, Squamous Cell / surgery. Humans. Male. Paget Disease, Extramammary / surgery. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20674695.001).
  • [ISSN] 1558-318X
  • [Journal-full-title] The Urologic clinics of North America
  • [ISO-abbreviation] Urol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Chew YK, Noorizan Y, Khir A, Brito-Mutunayagam S, Prepagaran N: The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose. Med J Malaysia; 2008 Oct;63(4):339-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of paramedian forehead flap reconstruction after wide excision of basal cell carcinoma of the nose.
  • Basal cell carcinoma (BCC) is an indolent, slow-growing malignant skin tumour.
  • The nose is a common site for malignant skin tumours, such as basal cell carcinoma and squamous cell carcinoma because it is exposed to the sun.
  • Excision of the BCC will leave the nose with a soft tissue defect which requires reconstruction.
  • This report illustrates a case of BCC of nose whereby a wide excision and reconstruction was performed with a paramedian forehead flap.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Nose Neoplasms / surgery. Rhinoplasty / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19385500.001).
  • [ISSN] 0300-5283
  • [Journal-full-title] The Medical journal of Malaysia
  • [ISO-abbreviation] Med. J. Malaysia
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  •  go-up   go-down


99. Babilas P, Landthaler M, Szeimies RM: Photodynamic therapy in dermatology. Eur J Dermatol; 2006 Jul-Aug;16(4):340-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, topical photodynamic therapy (PDT) has received approval for the treatment of dermato-oncologic conditions like actinic keratoses, Bowen's disease, in-situ squamous cell carcinoma and basal cell carcinoma in many countries all over the world.
  • Due to the easy accessibility of skin to light activation, incoherent lamps or LED arrays are suitable for PDT.
  • Either cytotoxic effects resulting in tumor destruction or immunomodulatory effects improving inflammatory skin conditions are induced.
  • Treating superficial non-melanoma skin cancer, PDT has been shown to be highly efficient despite the low level of invasiveness.
  • [MeSH-major] Photochemotherapy. Skin Diseases / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Carcinoma, Basal Cell / drug therapy. Humans

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935788.001).
  • [ISSN] 1167-1122
  • [Journal-full-title] European journal of dermatology : EJD
  • [ISO-abbreviation] Eur J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 80
  •  go-up   go-down


100. Ouyang YH: Skin cancer of the head and neck. Semin Plast Surg; 2010 May;24(2):117-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancer of the head and neck.
  • The majority of skin cancers of the head and neck are nonmelanoma skin cancers (NMSC).
  • Basal cell carcinoma and squamous cell carcinoma are the most frequent types of NMSC.
  • Malignant melanoma is an aggressive neoplasm of skin, and the ideal adjuvant therapy has not yet been found, although various options for treatment of skin cancer are available to the patient and physician, allowing high cure rate and excellent functional and cosmetic outcomes.
  • Sunscreen protection and early evaluation of suspicious areas remain the first line of defense against skin cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22550432.001).
  • [ISSN] 1535-2188
  • [Journal-full-title] Seminars in plastic surgery
  • [ISO-abbreviation] Semin Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3324239
  • [Keywords] NOTNLM ; Basal cell carcinoma / Mohs' micrographic surgery / melanoma / nonmelanoma skin cancer / squamous cell carcinoma
  •  go-up   go-down






Advertisement